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REPORT
Еxplаnаtory  notе  to  thе  dіplomа  projесt  “Organisation  and  technology  of
vaccine  delivery  to  Ukraine”  consists  of  139 pаgеs,  43  fіgurеs,  5  tаblеs,  2
Appendix and 62 sourсеs usеd.
Key words: AIRLINE, VACCINE, COVID-19, DELIVERY, STRATEGY,
ADR,  DANGEROUS  GOODS,  INVERSMENT ANALYSIS,  COMPETITION,
WIZZ  AIR,  UKRAINE  INTERNATIONAL  AIRLINES,  COMPETITIVE
FORCES, SWOT ANALYSIS, COVAX.
Objесt of study: organisation and technology of vaccine delivery to Ukraine.
Subjесt of study: сalculation of the cost of delivery of the first batch of covid
19 vaccine to Ukraine.
Purpose of thesis: analysis for choosing an airline that has a good name in the
aviation market that has experience in the transportation of dangerous goods and so
that the delivery of the vaccine to Ukraine would be at the most favorable position
for 2020.
The master’s thesis actuality: the relevance of robots for 2020-2021, taking
into account the best airlines at the moment, as well as the aircraft that will be
involved.
Recommendations: mаtеrіаls of the work can be used in further research on
related  topics.  In  case  of  using  the  materials  of  work,  the  source  should  be
provided.  
Projесtеd аssumptіons аbout thе objесt of study: an experienced airline in the
transportation of dangerous goods, the optimal calculation of fuel for the aircraft,
the choice of  the vaccine against  covid-19,  the delivery of  all  this in the most
optimal and profitable way for Ukraine.
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LІST OF SYMBOLS
ISO – International Organization for Standardization
NPAAC – National Pathology Accreditation Advisory Council
FTK – Freight Tonne-Kilometres
GDP – Gross Domestic Product
IAG – International Airlines Group
IOSA –IATA Operational Safety Audit
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PI – Profitability Index
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US – United States 
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ІАTА – Іntеrnаtіonаl Аvіаtіon Trаnsport Аssoсіаtіon
ІСАO – Іntеrnаtіonаl Сіvіl Аvіаtіon Orgаnіzаtіon
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Rеlеvаnсе of thе topіс. The search for a viable COVID-19 vaccine continues
around the world, but another pressing issue is already beginning to come to the
fore: how to transport billions of doses from factories to hospitals. The European
Union, as well as the United States, Britain, China and many other countries, have
already entered into preliminary agreements with major pharmaceutical companies
to ensure sufficient vaccine production capacity as soon as it becomes available.
While Europe boasts significant vaccine production potential and the block's
new Vaccination Strategy aims to oblige companies to provide treatment in the
EU, a logistical collapse could occur if politicians are not prepared properly. 
Vaccines  need  to  be  transported  according  to  strict  regulations,  under
temperature-controlled conditions to ensure their quality, and they must arrive at
their destination within a certain time frame to be effective.
According to IATA, it would take 8,000 Jumbo Jet 747 freighters to transport
just  one  batch  of  vaccine  to  an  estimated  7.8  billion  people  on  the  planet.
Companies currently have just over 400 such planes in their fleet worldwide. In
addition to the problems with air travel, there is also the issue of security.
The vaccine - which will be an extremely valuable commodity - will have to
be shipped to every corner of the planet, and IATA warns that tampering and theft
will become inherent problems.
 Road transport will also be a critical factor in delivery, but the International
Road Transport Union and the European Transport Workers' Federation continue
to warn that Europe suffers from a lack of safe and secure parking spaces for trucks
that could jeopardize delivery.
IATA recognizes that air cargo will only be part of the supply chain and other
modes of transport will play a role in door-to-door delivery of vaccine, especially
in  developing  countries. But  current  national  government  policies  will  limit
distribution efforts,  especially  when it  comes to border controls and quarantine
measures for key workers such as ground crew, truck drivers, and sailors.
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The European Commission has called on EU member states to sign a joint
document on border measures to harmonize the bloc's approach to quarantine and
travel criteria.
Objесt of study. Cargo transportation of dangerous goods to Ukraine. 
Subjесt of study. Thesis is devoted to the study environment of International
Airlines in order to define new strategy for  the fastest  and the chepest  cost  of
delivery of COVID-19 vaccine to Ukraine.
Mеthods of study. During the thesis preparation, different sources of data have
been used. The work is based primarily on secondary data, while it provides an
extensive  number  of  sources  due  to  popularity  of  this  target  in  the  literature.
Meanwhile, the primary data will be mainly used in the design part of the work,
while it should be based on the case study, active research how much vaccines
need to be bought, how much money will the state need, the calculation of the cost
of flights by different aircraft, the cost of the process, how much will the airline,
how  much  will  it  cost,  special  "packaging"  of  biological  materials  for  proper
transportation. Development of optimal vaccine delivery schemes.
As a result of this work it was proposed to create the most relevant way of
COVID-19 vaccine delivery to Ukraine and this project can be updated with more
related data and it can be presented more detailed plan.
Thе prасtісаl sіgnіfісаnсе of thе rеsults. The following work can create new
business model on Ukrainian aviation delivery market and give great influence on
ways of delivery of vaccines to Ukraine. By the way of creation the cheapest and
the fastest way of delivery.
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1.1. General characteristics and transportation of special cargoes
The official  definition  is  the  following:  “Articles  or  substances  which are
capable  of  posing  a  hazard  to  health,  safety,  property  or  the  environment  and
which are shown in the list of dangerous goods [published] in the ICAO Technical
Instructions, or which are classified according to these Instructions.”
There  is  a  wide  range  of  dangerous  goods,  some  of  them being  familiar
(detergents,  lacquers,  paints,  gasoline,  perfumes,  aerosols,  lithium  cells  or
batteries, phones for instance). We carry them, store them or use them, often in our
daily activity, in the personal or professional life. In flight, these items are subject
to temperature, pressure, vibration, acceleration which can be very different than
the conditions of storage or use at home.
In order to take into account this specific environment and ensure the safety
of the flight, the regulation introduces limitations or prohibitions for the transport
of these items.
The most widely applied regulatory scheme is that for the transportation of
dangerous goods. The United Nations Economic and Social Council issues the UN
Recommendations on the Transport of Dangerous Goods, which form the basis for
most  regional,  national,  and international  regulatory schemes.  For  instance,  the
International  Civil  Aviation  Organization  has  developed  dangerous  goods
regulations for air transport of hazardous materials that are based upon the UN
model but modified to accommodate unique aspects  of air  transport.  Individual
airline  and  governmental  requirements  are  incorporated  with  this  by  the
International  Air  Transport  Association  to  produce  the  widely  used  IATA
Dangerous  Goods  Regulations  (DGR).  Similarly,  the  International  Maritime
Organization (IMO) has developed the International Maritime Dangerous Goods
Code ("IMDG Code", part of the International Convention for the Safety of Life at
Sea) for transportation of dangerous goods by sea. IMO member countries have
also developed the HNS Convention to provide compensation in case of dangerous
goods spills in the sea.
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The Intergovernmental  Organisation for  International  Carriage by Rail  has
developed  the  regulations  concerning  the  International  Carriage  of  Dangerous
Goods by Rail ("RID", part of the Convention concerning International Carriage
by  Rail).  Many  individual  nations  have  also  structured  their  dangerous  goods
transportation regulations to harmonize with the UN model in organization as well
as in specific requirements.
The  Globally  Harmonized  System  of  Classification  and  Labelling  of
Chemicals  (GHS)  is  an  internationally  agreed  upon  system  set  to  replace  the
various classification and labeling standards used in different countries. The GHS
uses consistent criteria for classification and labeling on a global level.
Dangerous  goods  are  divided  into  nine  classes  (in  addition  to  several
subcategories) on the basis of the specific chemical characteristics producing the
risk.
Note: The graphics and text in this  work representing the dangerous goods
safety  marks  are  derived  from the  United  Nations-based  system of  identifying
dangerous goods. Not all countries use precisely the same graphics (label, placard
or text information) in their national regulations. Some use graphic symbols, but
without English wording or with similar wording in their national language. Refer
to the dangerous goods transportation regulations of the country of interest.
‘Dangerous goods’ are materials or items with hazardous properties which, if
not  properly controlled,  present  a  potential  hazard to  human health  and safety,
infrastructure and/ or their means of transport.
The transportation of dangerous goods is controlled and governed by a variety
of different  regulatory regimes,  operating at  both the national  and international
levels. Prominent regulatory frameworks for the transportation of dangerous goods
include  the  United  Nations  Recommendations  on  the  Transport  of  Dangerous
Goods, ICAO’s Technical Instructions, IATA’s Dangerous Goods Regulations and
the  IMO’s  International  Maritime  Dangerous  Goods  Code.  Collectively,  these
regulatory  regimes  mandate  the  means  by  which  dangerous  goods  are  to  be
handled, packaged, labelled and transported.
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Regulatory frameworks incorporate comprehensive classification systems of
hazards to provide a taxonomy of dangerous goods. Classification of dangerous
goods is broken down into nine classes according to the type of danger materials or
items present:
Class 1 - Explosives
Explosives are materials or items which have the ability to rapidly conflagrate
or detonate as a consequence of chemical reaction.
DGI are proficient in handling explosives, Class 1 Dangerous Goods. DGI
have  the  ability  to  service  all  customer  requests  pertaining  to  the  logistics  of
explosives; packing, packaging, compliance, freight forwarding and training.
Reason for Regulation
Explosives  are  capable  by  chemical  reaction  of  producing  gases  at
temperatures, pressures and speeds as to cause catastrophic damage through force
and/or  of  producing otherwise  hazardous amounts of  heat,  light,  sound,  gas or
smoke
Sub-Divisions:
Division 1.1: Substances and articles which have a mass explosion hazard;
Division 1.2: Substances and articles which have a projection hazard but not a
mass explosion hazard;
Division 1.3: Substances and articles which have a fire hazard and either a
minor blast hazard or a minor projection hazard or both;
Division 1.4:  Substances  and articles  which present  no  significant  hazard;
only a small hazard in the event of ignition or initiation during transport with any
effects largely confined to the package;
Division  1.5:  Very  insensitive  substances  which  have  a  mass  explosion
hazard;
Division  1.6:  Extremely  insensitive  articles  which  do  not  have  a  mass
explosion hazard.
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Pic 1.1 Classification and labeling of dangerous goods
Commonly Transported Explosives
Ammunition/cartridges,  Fireworks/pyrotechnics,  Flares,  Blasting  caps  /
detonators, Fuse, Primers, Explosive charges (blasting, demolition etc), Detonating
cord, Air bag inflators, Igniters, Rockets, TNT / TNT compositions, RDX / RDX
compositions, PETN / PETN compositions.
Class 2: Gases
Gases which are compressed, liquefied or dissolved under pressure as detailed
below. Some gases have subsidiary risk classes; poisonous or corrosive.
- Flammable Gas: Gases which ignite on contact with an ignition source, such
as acetylene, hydrogen, and propane.
- Non-Flammable Gases: Gases which are neither flammable nor poisonous.
Includes  the  cryogenic  gases/liquids  (temperatures  of  below -100 °C)  used for
cryopreservation and rocket fuels, such as nitrogen, neon, and carbon dioxide.
- Poisonous Gases: Gases liable to cause death or serious injury to human
health if inhaled; examples are fluorine, chlorine, and hydrogen cyanide.
Fig.1.2 Classification and labeling of dangerous goods
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Class 3: Flammable Liquids
Flammable liquids included in Class 3 are included in one of the following
packing groups:
- Packing Group I, if they have an initial boiling point of 35°C or less at an
absolute pressure of 101.3 kPa and any flash point, such as diethyl ether
or carbon disulfide;
- Packing Group II, if they have an initial boiling point greater than 35°C
at an absolute pressure of 101.3 kPa and a flash point less than 23°C,
such as gasoline (petrol) and acetone;
- Packing Group III, if the criteria for inclusion in Packing Group I or II
are not met, such as kerosene and diesel.
Note:  For  further  details,  check  the  Dangerous  Goods  Transportation
Regulations of the country of interest.
Fig. 1.3 Classification and labeling of dangerous goods
Class 4: Flammable Solids
-  Flammable  Solids:  Solid  substances  that  are  easily  ignited  and  readily
combustible (nitrocellulose, magnesium, safety or strike-anywhere matches).
-  Spontaneously  Combustible:  Solid  substances  that  ignite  spontaneously
(aluminium alkyls, white phosphorus).
- Dangerous when Wet: Solid substances that emit a flammable gas when wet
or react violently with water (sodium, calcium, potassium, calcium carbide).
Fig. 1.4 Classification and labeling of dangerous goods
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Class 5: Oxidizing Agents and Organic Peroxides
-  Oxidizing  agents  other  than  organic  peroxides  (calcium  hypochlorite,
ammonium nitrate, hydrogen peroxide, potassium permanganate)
- Organic peroxides, either in liquid or solid form (benzoyl peroxides, cumene
hydroperoxide).
Fig. 1.5 Classification and labeling of dangerous goods
Class 6: Toxic and Infectious Substances
Toxic substances which are liable to cause death or serious injury to human
health if inhaled, swallowed or by skin absorption (potassium cyanide, mercuric
chloride).
(Now PGIII) Toxic substances which are harmful to human health (N.B this
symbol  is  no  longer  authorized  by  the  United  Nations)  (pesticides,  methylene
chloride).
Biohazardous substances; the World Health Organization (WHO) divides this
class into two categories: Category A: Infectious; and Category B: Samples (virus
cultures, pathology specimens, used intravenous needles).
Fig. 1.6 Classification and labeling of dangerous goods
Class 7: Radioactive substances
Radioactive substances comprise substances or a combination of substances
which emit ionizing radiation (uranium, plutonium).
Fig. 1.7 Classification and labeling of dangerous goods
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Class 8: Corrosive substances
Corrosive  substances  are  substances  that  can  dissolve  organic  tissue  or
severely corrode certain metals:
- Acids: sulfuric acid, hydrochloric acid;
- Alkalis: potassium hydroxide, sodium hydroxide.
Fig. 1.8 Classification and labeling of dangerous goods
Class 9: Miscellaneous
Hazardous substances that do not fall into the other categories (asbestos, air-
bag inflators, self inflating life rafts, dry ice). 
Fig. 1.9 Classification and labeling of dangerous goods
Miscellaneous  dangerous  goods  are  substances  and  articles  which  during
transport  present  a  danger  or  hazard  not  covered  by  other  classes.  This  class
encompasses,  but  is  not  limited  to,  environmentally  hazardous  substances,
substances that are transported at elevated temperatures, miscellaneous articles and
substances, genetically modified organisms and micro-organisms and (depending
on  the  method  of  transport)  magnetized  materials  and  aviation  regulated
substances.
DGI  are  proficient  in  handling  miscellaneous  dangerous  goods,  Class  9
Dangerous Goods. DGI have the ability to service all customer requests pertaining
to  the  logistics  of  miscellaneous  dangerous  goods;  packing,  packaging,
compliance, freight forwarding and training.
Reason for Regulation
Miscellaneous dangerous goods present a wide array of potential hazards to
human health and safety, infrastructure and/ or their means of transport.
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Transport documents
One of the transport regulations is that, as an assistance during emergency
situations, written instructions how to deal in such need to be carried and easily
accessible in the driver’s cabin. A license or permit card for hazmat training must
be presented when requested by officials.
Dangerous goods shipments also require a special declaration form prepared
by  the  shipper.  Among the  information  that  is  generally  required  includes  the
shipper's name and address; the consignee's name and address; descriptions of each
of the dangerous goods, along with their quantity, classification, and packaging;
and emergency contact information. Common formats include the one issued by
the International Air Transport Association (IATA) for air shipments and the form
by the International Maritime Organization (IMO) for sea cargo.
DANGEROUS GOODS TRANSPORTATION RULES
Dangerous goods are substances that are either not allowed for transportation
at all or require a special permission for transportation. A permit can be obtained if
the owner and the carrier have the correct documents, have special transport, have
drawn up a detailed itinerary, and the delivery of dangerous goods is carried out by
specially trained personnel. The main thing that needs to be taken care of is that the
substances are safely and securely loaded into special containers or vehicles. Only
in this case you can be sure that the dangerous cargo will not be damaged on the
way and will not harm anyone.
The Rules for the Carriage of Dangerous Goods by Road (hereinafter referred
to as the Rules)  determine the procedure, as well as the basic requirements for
ensuring  the  safety  of  these  carriage  by  road  throughout  Ukraine  and  are
mandatory for all Ukrainian carriers.
International road transport of dangerous goods is carried out in accordance
with the European Agreement on the International Carriage of Dangerous Goods
by Road (hereinafter - ADR) and other international agreements of Ukraine.
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Dangerous  goods  are  allowed  to  be  transported  by  road  only  if  they  are
admitted for carriage in accordance with the requirements of ADR and these Rules
and if all requirements for the carriage of such goods are met.
Radioactive materials are transported by road within the territory of Ukraine
in accordance with the Rules of Nuclear and Radiation Safety for the Carriage of
Radioactive  Materials  approved  by  order  of  the  State  Committee  for  Nuclear
Regulation of Ukraine No. 18 dated May 23, 2001, registered with the Ministry of
Justice of Ukraine on July 13, 2001, No. 591/5782, and these Rules, in the part that
is not regulated by the specified document.
The subjects of the transportation of dangerous goods are obliged to use the
appropriate type and degree of hazard measures aimed at preventing accidents, and
in the event of an accident that has taken place, measures that make it possible to
limit the serious consequences of this accident as much as possible.
The TERMS that are used in these Rules have the following meaning:
A tank truck is a specialized vehicle that, due to its design and equipment, is
intended for the transport of liquids, gases or powdery or granular substances and
includes one or more built-in tanks.
Multi-element gas container - a container that consists of elements connected
to each other by a manifold and installed in a frame. The elements of a multi-
element gas container are: cylinders, tubes, cylinder connections, pressure drums,
as well as tanks intended for the carriage of gases of hazard class 2 with a capacity
of over 450 liters.
Large container - a container with an internal volume of over 3 cubic meters.
Built-in tank - a tank that has a capacity of over 1000 liters and is permanently
installed on a vehicle (which in this case becomes a tank truck) or is an integral
part of the frame of such a vehicle.
Large-sized packaging - a container that consists of an outer container that
contains products or an inner container intended for mechanized processing, has a
net weight of over 400 kg or a capacity of over 450 liters and its volume does not
exceed 3 cubic meters.
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Open container - an open top container or container based on a platform.
Open vehicle - a vehicle, the platform of which is equipped only with sides.
Responsible for filling - a legal or natural person who loads dangerous goods
into a tank (tank truck, demountable tank, portable tank or tank container) and (or)
a vehicle, large or small container for the carriage of dangerous goods in bulk (in
bulk), as well as into a battery vehicle or multi-element gas container.
Consignor of  dangerous goods -  a  legal  or natural  person specified in the
shipping documents, who prepares and submits this cargo for transportation.
Waste - any substances, materials and objects that are obtained in the process
of  human  activity  and  do  not  have  further  use  at  the  place  of  formation  or
identification and which their owner must dispose of by recycling or disposal.
Packing  group  is  a  group  to  which  some  substances  can  be  assigned
depending on the degree of danger they are characterized by. Packing groups have
the following meanings:
packing group I - substances with a high degree of danger;
packing group II - substances with medium hazard;
packing group III - substances with a low degree of danger.
Closed container - container with a solid shell, which has a rigid roof, rigid
side and end walls and a bottom. This term includes a container with a roof that
can be opened and that can be closed during transport. Closed vehicle means a
vehicle with a body that can be closed.
Removable tank means any tank other than a built-in tank (portable tank, tank
container or part of a vehicle - batteries or multi-element gas container) with a
capacity  of  more  than  450  liters,  which  is  intended  for  the  carriage  of  goods
without  reloading  and  is  usually  subject  to  handling  only  in  an  empty  state.
Container is an item of transport equipment (cage or other similar device) that:
a) intended for multiple use and has a permanent purpose;
b) specially designed to facilitate the carriage of goods by one or more modes
of transport without intermediate reloading of goods;
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c) equipped with devices that facilitate its securing and reloading from one
vehicle to another;
d) designed for easy loading and unloading Intermediate bulk container - rigid
or flexible portable packaging that has a capacity: not more than 3.0 m3 (3000 l)
for solids and liquids of packing groups II and III:
-  not more than 1.5 cubic meters for  packing group I solids,  if  soft,  rigid
plastic, stacked, cardboard or wooden intermediate bulk containers are used;
- not more than 3.0 cubic meters for solids of packing group I, if medium-
duty metal containers for bulk goods are used;
- no more than 3.0 cubic meters for radioactive material of the 7th hazard
class.
United Nations Number is a four-digit identification number for a substance
or  article  in  accordance  with  the  United  Nations  Recommendations  on  the
Transport of Dangerous Goods. Model Regulations (ST / SG / AC.10 / 1 / Rev.13).
The nominal capacity of the vessel is the nominal volume of the hazardous
substance that is placed in the vessel, expressed in liters. In the case of compressed
gas cylinders, the nominal capacity of the cylinder is the capacity when filled with
water.
Recipient  of  dangerous goods is a legal  or  natural  person specified in the
shipping documents who receives dangerous goods from the carrier.
A heating device is a device that directly uses liquid or gaseous fuel and does
not use heat that is removed from the vehicle engine.
Tank container operator (portable tank) - a legal or natural person in whose
name the registered tank container (portable tank).
Package - A casing that is used by a single shipper to combine one or more
packages into a single unit in order to facilitate loading and unloading operations.
Bulk  transportation -  transportation  of  unpackaged  solids  and products  in
vehicles or containers. This term does not apply to packaged goods and substances
that are transported in tanks.
23
Carrier of dangerous goods - a legal or natural person who carries out the
transportation of dangerous goods in a certain way.
Portable tank - tank for combined transport, which has a capacity of over 450
liters and consists of a body with service equipment required for the transport of
hazardous substances. This tank must be capable of loading and unloading without
removing its structural equipment. It must ensure loading, reloading and unloading
in a filled state.
Full load - any cargo of one shipper, during the transportation of which a
vehicle  or  a  large  container  is  loaded  only  with  this  cargo and  all  loading  or
unloading operations of which are carried out in accordance with the instructions
of the shipper or consignee.
1.2. Conditions of transport schemes creation for special cargo delivery
It is obvious that ensuring fast delivery of goods will require the use of faster
modes of transport, such as air, which will increase the cost of delivery. Improving
the  quality  of  delivery  also  very  often  leads  to  an  increase  in  the  cost  of
transportation.  There  is  an  increase  in  the  share  of  goods  that  require  special
conditions of carriage, as well as increasing requirements for the global transport
system. Transportation of special cargo with the participation of air transport is
currently of great importance, both for the transport complexes of countries and for
the world economy as a whole. Using the speed of air transport,  TEP has also
significantly expanded the range of its services.
Offers for the transportation of special cargo are widely represented in the
market  of  freight  forwarding services.  That  is,  the  concept  of  special  cargo is
widely  used  in  the  practice  of  carriers  and  TEP  in  the  organization  of
transportation of goods by different modes of transport
The specific properties of special cargo significantly affect the entire process
of organization and technology of transportation, they can be aggressive towards
other goods,  vehicles  and warehouses.  Aggressive  properties  can damage other
loads, damage vehicles and warehouses, and create hazards during transportation.
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On the other hand, many categories of special  loads are exposed to aggressive
properties.  The  consequences  of  exposure  to  aggressive  properties  can  be
deterioration or loss of cargo.
The presence of specific properties in the cargo, in contrast to general cargo,
contributes to the creation of risky situations in the process of transportation. When
transporting them, it is necessary to comply with the requirements for acceptance
of cargo for transportation, packaging, processing and loading, documentation, etc.
When performing TEP functions of the organizer of cargo delivery in a mixed
connection, the components of the delivery cost and their ratio change greatly, and
in the structure of the delivery cost it is the aviation tariffs that are the largest part
of the costs.  TEP, as the organizer of cargo delivery, becomes the generator of
tariffs for delivery of cargoes in the mixed connection. The nature of the cargo also
significantly affects the economic efficiency of forwarding and pricing.
When  delivering  special  cargo,  transport  processes  can  have  very  serious
consequences of exposure to risks - even to the complete loss of cargo properties,
or  negative  impact  on  the  environment,  vehicles  and  other  goods,  and  the
probability of consequences higher than the delivery of general cargo.
Also, in calculating the economic results of ideal and optimal delivery, the
author did not pay attention to the quantitative assessment of the impact of risks
associated with the processes of transportation of goods. According to the author,
the greatest  impact  on the economic  results  of  supply  have  such stages  of  the
supply chain as ordering, customs clearance and acceptance of goods. Therefore,
the organization of the activities of TEP, engaged in the delivery of special goods,
has certain differences, more diverse transport risks and requires a separate study.
The analysis of the freight market with air transport, the specific conditions of
the movement and storage of different types of special cargo, particularly those
that  have  perishable  and  hazardous  properties,  systematically  sources  of  risk
analysis made of the possible consequences of the occurrence of risk events and
proved their effect economic financial and economic activities of the airport.
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Effectively manage these risks cannot be transmission or ignoring risks, as it
can lead to disastrous consequences (complete loss of consumer product quality,
damage  to  vehicles  and  other  goods,  etc.).  Defined  risk  group  requires
management decisions aimed at preventing risk events guaranteed at all times due
to increased shipping costs for organizations of all delivery processes. On the other
hand, these costs may not exceed, as a client opportunities and market price of
delivery.
Highlight  traffic  parameters,  factors  that  affect  the  costs  and  revenues  of
airport in the delivery of special goods that have both dangerous and perishable
properties.  It  was  found  that  the  most  significant  impact  on  the  efficiency  of
delivery are characteristics of loading units, the size and quantity of cargo parties,
tariff rates, which largely operates freight forwarding company.
That  was  proposed  the  system  of  special  categories  of  cargo  delivery
performance management, that is formed the subsystem of expanses performance,
risk performance and fees and tariffs performance. In sum all these performances
allow to control the process of delivery by each stage and providing the given level
of profitability.
The paper detailed data components and subsystems of the content delivery
options special cargo in car and aircraft traffic. Management options loading units
in the organization of special cargo delivery enables on the one hand to manage
risks on the other hand the cost of shipping cargo that will determine the thrust of
calculating  the  cost  of  delivery  and  affordable  prices  and  thereby  ensure  the
economic efficiency of the airport during the planning period. The ability to design
cost of airport in the chain of delivery of special cargo by selecting combinations
of  traffic  makes  it  possible  to  increase  the  yield of  special  cargo delivery and
flexibility  to  change  the  price  of  FCC services,  depending  on  the  competitive
situation and fluctuations in demand.
The  study  of  international  experience  of  civil  aviation  in  terms  of  legal
transport of dangerous goods allowed to identify legislation needed for  priority
entry to Ukraine in order to regulate the transport complex of the country on the
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Transport of special cargo: the law on transportation of special cargo and insurance
law  transport  of  special  cargo,  developed  taking  into  account  the  recent
recommendations  of  the  United  Nations,  ICAO  and  other  international
organizations. The convergence of national transport legislation with special cargo
transportation with the relevant international legal instruments must, above all, to
integrate  the  transport  system  of  Ukraine  in  the  global  improvement  of  the
operational efficiency of international transport routes on time, cost and level of
service.
Analysis of regulations governing the transport processes of special categories
of goods in the country, found that in civil aviation are mostly outdated standards,
designed for processes organization of special categories of cargo of aircraft using
imperfect types of ground equipment. To improve traffic safety in air transport it is
proposed to carry out the development and implementation of scientifically based
standards on procedures related to the transport of specific categories of goods, in
the form of manuals, instructions and guidance on the technical characteristics of
the types of aircraft operated, machinery, equipment, modern requirements safety
in air transport and training of aviation personnel
Currently, the issue of control of the organization of transportation of special
categories  of  goods  and  their  impact  on  the  safety  of  air  transport  are  at  the
junction of the two administrative structures Civil Aviation Committee, Office of
Aviation  Security  and  Safety  Inspectorate.  As  a  result,  the  problem  of
transportation of  special  categories  of  goods are  overlooked.  To streamline  the
organization of transportation of special categories of goods in the thesis work the
creation of a separate structural unit of the Committee of civil aviation and air
transport is proposed.
The introduction of these structures will provide:
– permanent control over special categories of cargo transportation in the
form of specialized inspection;
– development of compliance and regulatory framework;
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– coordination for  training and licensing of  aviation  professionals  and
shippers;
– analysis  of  factors  influencing  the  transport  of  special  categories  of
goods on the safety of air transport;
– guidelines for production activities;
– provide information to cargo shippers, agents, air passengers;
– recording of special categories of traffic loads.
1.3. Features of biological cargo transportation
The  transport  of  biological  materials,  including  infectious  substances,  is
covered by international,  regional  or  national  regulations that  are  updated on a
regular basis and are widely accessible via the internet, or through commercial and
regulatory transportation affiliates.
The international regulations for the transport of infectious substances by any
mode  of  transport  are based  upon  the  Recommendations  on  the  Transport  of
Dangerous  Goods  made  by  the Subcommittee  of  Experts  on  the  Transport  of
Dangerous  Goods  (UN  SCETDG),  a  subcommittee  of the  United  Nations
Economic and Social Council. The Recommendations are presented in the form of
Model Regulations covering air, rail, road, sea and also include international mail.
The  World Health  Organization  (WHO)  guidance  document  on  “Transport  of
Infectious Substances” summarising the different transport regulations is regularly
updated.  Countries,  other  international organisations,  international  treaties  and
conventions such as the International Air Transport Association (IATA), the World
Customs  Organization  (WCO),  the  Convention  on  International  Trade in
Endangered  Species  (CITES),  and  the  Convention  on  Biodiversity  (CBD),
especially the Nagoya Protocol, provide additional guidance and regulations that
should be considered in planning the transportation of biological materials.
All personnel involved in the packaging, labelling and shipping of biological
materials must be appropriately trained, certified, competent and knowledgeable of
the relevant national, regional and international regulations. Biological materials
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should be transported to ensure a rapid and reliable system for delivery to the
recipient using individuals such as professional logistics service providers that are
trained and competent in the shipping and transportation process.
The  efficient  transport  and  transfer  of  biological  materials  requires  co-
ordination  between  the  sender  (shipper, consignor),  the  logistic  providers,  the
carrier and the recipient (consignee) to ensure safe transport and arrival on time
and in proper condition.
Classifiacation and categorisations
When transporting biological materials, the sender must determine whether
the  material  should  be  classified  as dangerous  goods or  not.  Dangerous  goods
(hazardous materials, HAZMAT) are materials that can harm humans, animals and
other  living  organisms,  property,  or  the  environment,  and  their  transport  is
regulated by United Nations (UN) regulations. 
Table1.1
Classification of packing of biological dangerous goods
Dangerous goods
classifications
Categorisation Proper shipping
name
UN number Packing
instruction/packaging
requirements
Class 6,
Division 6.2
Category A Substance,
affecting humans
UN 2814 P620
Substance,
affecting animals
UN 2900
Class 6,
Division 6.2
Category B Biological
substance,
Category B
UN 3373 P650
Class 6,
Division 6.2
Exempt
human/animal
specimens
Exempt
human/animal
specimens
N/A Triple packaging
not subject to
dangerous goods
regulations(DGR)
Biological materials
not
subject to DGR
N/A N/A N/A
Class 9 GMMOs and GMOs
not classified
as Category A or B
Genetically
modified organisms/
microorganisms;
UN 3245 P904 (ICAO/IATA PI
959), IBC99
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The sender (shipper, consignor) is  responsible for providing the applicable
documentation (e.g. certifications, permits) required by the national authorities of
the  countries  of  export,  transhipment  and  import  as  well  as ensuring  that  the
shipment also complies with all other applicable regulations.
Dangerous goods are assigned a UN number and proper shipping name based
on the classification of the dangerous goods. The transport regulations assign a
packing instruction against the UN number and proper shipping name, to specify
the packaging/packing method to ensure that the dangerous goods do not pose a
hazard in transport. Of the biological materials are classified as dangerous goods
and are assigned to UN 2814, UN 2900, UN 3373, or UN 3291, as appropriate. In
addition,  Genetically  Modified  Microorganisms  (GMMOs)  and  Genetically
Modified Organisms (GMOs) are classified as Class 9 and assigned to UN 3245 if
they are not classified as Category A or Category B.
Category A
Substance is an infectious substance which is transported in a form that, when
exposure to it occurs, is capable of causing permanent disability, life-threatening or
fatal disease in otherwise healthy humans or animals. Assignment to UN 2814 or
UN  2900  (see  Table  1)  must  be  based  on  the  known  medical  history  of  the
animal(s), signs and individual circumstances of the specimen source, and endemic
local  disease  conditions,  or professional  judgement  concerning  individual
circumstances of  the source,  human or animal. Some organisms are considered
Category A only when in culture form (e.g. Bacillus anthracis,  foot and mouth
disease virus). Indicative examples of substances that meet these criteria. The table
is not  exhaustive.  Infectious substances,  including new or  emerging pathogens,
which  do  not  appear  in  the  Table but  which  meet  the  same  criteria  must  be
assigned  to  Category  A.  In  addition,  if  there  is  doubt  as  to  whether  or not  a
substance meets the criteria it must be assigned to Category A.
Some infectious substances may have a high economic or trade impact on
specific  countries  should  there  be release  to  the  environment.  Therefore,  other
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infectious substances may be added to the list by individual countries (e.g. cultures
of Newcastle disease virus where the virus is exotic to the country or region).
Medical or clinical waste containing Category A infectious substances shall
be  assigned  to  UN  2814  or  UN  2900 as  appropriate.  Solid  medical  waste
containing Category A infectious substances generated from the medical treatment
of humans or  veterinary treatment of  animals may be assigned to UN 3549. It
should be noted that Medical or clinical waste from bio-research or liquid waste
must not be assigned to UN3549.
Category B
Biological materials containing pathogens which do not meet the criteria for
Category A (i.e. do not cause lifethreatening disease to humans or animals) shall
be assigned to Category B (UN 3373)
Typically a specimen with a high likelihood to contain pathogenic organisms
shipped for disease diagnosis (e.g. confirmatory diagnosis of suspected or clinical
cases,  specimens for  differential  diagnosis,  such as  blood samples for  classical
swine fever or sheep pox diagnostics or throat samples from chickens for avian
influenza) can be assigned to Category B.
It  is  important  to  note  that  unlike  cultures,  patient  specimens  which may
contain infectious microorganisms listed as „cultures only‟ in Table 3 (Category A
infectious substances)  do not  require  Category A transport  practices.  For these
specimens Category B transport practice should be applied. In this case, although
directly  collected specimens  (e.g.  serum)  can  be  shipped  as  Category  B,  pure
cultures of the same pathogens must follow the requirements of Category A due to
the characteristics of the specific organism. Some examples are classical swine
fever  virus  isolates  or  sheep  pox virus  isolates  (see  Table  3).  Specimens from
animals intentionally infected with Category A pathogens must be sent as Category
A, even if they are assigned to Category A (cultures only). Shipments of cultures
of non-category A agents can be assigned to Category B.
Medical or clinical waste containing Category B infectious substances shall
be assigned to UN 3291.
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Animal specimens for which there is minimal likelihood that pathogens are
present can be transported as Exempt Specimens. Examples of specimens in the
veterinary  field  which  may  be  transported  as  exempt  include specimens  from
surveillance  studies,  export  controls  of  healthy  animals  (e.g.  certification  of
freedom  from classical  swine  fever)  or  determination  of  immune  status  of
individual  animals  or  populations  (post-vaccination). These  specimens  are  not
subject  to  dangerous  goods  regulations  if  the  specimen  is  transported  in  a
packaging that will prevent any leakage and that is marked appropriately.
Biological materiarls not subject to Dangerous Good Regulations (DGR).
Based on the known medical history of the animal(s), signs and individual
circumstances of the source of the biological materials, and endemic local disease
conditions, the following are not subject to dangerous goods regulations, unless
they meet the criteria for inclusion in another class (such as Class 9):
- biological materials that do not contain infectious substances
- biological materials containing microorganisms that are non-pathogenic
to humans or animals;
- biological materials in a form in which any pathogens present have been
neutralised or inactivated such that they no longer pose a health risk;
- environmental specimens (including food and water specimens) that are
not considered to pose a significant risk of infection;
- dried blood spots, collected by applying a drop of blood onto absorbent
material.
There may be specific regulations in place in some countries for the shipment,
export or import of nucleic acids.
A Category A substance is an infectious substance that is transported in a
form that, when exposure to it occurs, is capable of causing permanent disability,
or  a  life-threatening  or  fatal disease  in  otherwise  healthy  humans  or  animals.
Infectious substances meeting these criteria that cause disease in humans or both in
humans and animals  must  be  assigned  to  UN 2814.  Infectious  substances  that
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cause disease only in animals must be assigned to UN 2900. These are classified
under IATA Hazard Class 6.2 and IATA Packing Instruction 602.
Assignment  to  Category  A  and  the  proper  shipping  name,  ‘Infectious
substances, affecting humans’ or ‘Infectious substances, affecting animals’, must
be based on the known medical history and symptoms of the source human or
animal, endemic local conditions, or professional judgment concerning individual
circumstances of the source human or animal. Indicative examples of substances
that meet these criteria are given in Appendix А.
A Category B substance is an infectious substance that  does not meet the
criteria for inclusion in Category A. Infectious substances in Category B must be
assigned to UN 3373, and their proper shipping name is ‘Biological Substances,
Category  B’. Human  or  animal  material  including  but  not  limited  to  excreta,
secreta, blood and its components, tissue and tissue fluids, and body parts, being
transported  for  purposes  such  as research,  diagnosis,  investigational  activities,
disease treatment and prevention, are assigned to UN 3373. These are classified
under IATA Hazard Class 6.2 and IATA Packing Instruction 650.
Biological products
Biological products are those products derived from living organisms which
are  manufactured  and distributed  in  accordance  with  the  requirements  of
appropriate national authorities, which may have special licensing requirements,
and are used either for prevention, treatment, or diagnosis of disease in humans or
animals,  or  for  development,  experimental  or  investigational  purposes  related
thereto. They include, but are not limited to, finished or unfinished products such
as vaccines.
Genetically modified microorganisms and organisms
Genetically modified microorganisms and organisms are microorganisms and
organisms in which genetic material has been purposely altered through genetic
engineering in a way that  does not  occur naturally.  Those genetically modified
microorganisms and organisms that  do not  meet the definition of  an infectious
substance shall be assigned to UN 3245 and shipped following Packing Instruction
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P904 (ICAO/IATA PI913) – this is not considered further in these guidelines.
Medical or clinical wastes
Medical or clinical wastes are wastes derived from the medical treatment of
animals or  humans or from bio-research.  Medical  or  clinical  wastes  containing
Category A infectious substances shall be assigned to UN 2814 or UN 2900 as
appropriate.  Medical  or  clinical  wastes  containing  Category  B infectious
substances,  or  which  are  reasonably  believed  to  have  a  low  probability  of
containing infectious  substances,  shall  be  assigned  to  UN  3291  and  shipped
following Packing Instruction P621 (ICAO/IATA PI622) – this is not considered
further in these guidelines.
Patient specimens
These  are  human  or  animal  materials,  collected  directly  from  humans  or
animals, including, but not limited to, excreta, secreta, blood and its components,
tissue and tissue fluid swabs, and body parts being transported for purposes such as
research, diagnosis, investigational activities, disease treatment and prevention.
Cultures (laboratory stocks)
Cultures are the result  of a process by which pathogens are amplified and
propagated in order to generate high concentration, thereby increasing the risk of
infection when exposure to them occurs. This definition refers to cultures prepared
for the intentional generation of pathogens and does not include cultures intended
for diagnostic and clinical purposes.
Cultures  are  the  result  of  a  process  by  which  pathogens  are  intentionally
propagated. This definition does not include human or animal patient specimens as
defined below. Cultures may be classified as Category A or Category B, depending
on the microorganism concerned.
The following additional definition has been adopted for the 14th edition of
the United Nations Model Regulations. ICAO has approved the application of this
new text for air transport from 2005, as described in the Addendum No.2 to Doc
9284-AN/905, published in May 2005.
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Fig 1.10 Hazard classification flow chart
*Refer  to  ISBT  128  (November  2006)  and  NPAAC’s  Requirements  for
Procedures  Related  to  the  Collection,  Processing, Storage  and Issue  of  Human
Haemopoietic Progenitor Cel.
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1.4. Technology of biological materials delivery and requirements for 
their packaging
1.4.1 Requirements for biological materials packaging
All biological materials should be packaged and transported in accordance
with local, national and international regulations. The procedures should minimise
the risk of exposure for those engaged in transportation and should protect  the
environment  and  susceptible  animal  populations  from  potential  exposures.
Additionally,  ineffective packaging  that  does  not  protect  specimens  or
preservatives  (e.g.  ice)  from  damage  or  prevent  leakage  will  likely delay  the
delivery  of  the  shipment  to  the  laboratory,  delaying  or  preventing  critical
laboratory analyses from being performed. Biological materials should always be
packaged and transported to protect the integrity of the specimens, as well as to
avoid  cross-contaminating  other  specimens  and  environmental  contamination.
Minimum requirements for the transport of specimens follow the principle of triple
packaging, consisting of three layers as described below:
- a primary receptacle;
- a secondary packaging;
- an outer packaging;
of which either the secondary or the outer packaging must be rigid.
A primary receptacle
A primary receptacle, leak-proof for liquids or sift-proof for solids containing
the specimen. Primary receptacle(s) must be packed into the secondary packaging
with enough absorbent material (e.g. cellulose wadding, paper towels, house hold
paper, cotton balls) to absorb all fluid in case of breakage.
Even though the regulations do not prohibit glass, primary receptacles should
preferably be nonbreakable.  In addition, they must  not contain any sharps (e.g.
vacutainer with needle), particularly when using soft secondary or outer containers.
If screw cap vials are used, they shall be secured by e.g. tape. A flip-top vial must
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not be used. Biological materials should always be packaged and transported to
protect  the  integrity  of  the specimens,  as  well  as  to  avoid  cross-contaminating
other specimens and environmental contamination.
A Secondary receptacle
A second durable, leak-proof packaging to enclose and protect the primary
receptacle(s) (e.g. sealed plastic bag, plastic container, screw-cap can).
The  primary  receptacle  or  the  secondary  packaging  shall  be  capable  of
withstanding,  without leakage, an internal  pressure of  95 kPa (0.95 bar)  in the
range of –40°C to +55°C (–40°F to +130°F).
Secondary  packaging  is  placed  in  outer  shipping  packaging  (e.g.  sturdy
insulated  fibre  board  box)  with suitable  cushioning  material.  Outer  packaging
protects the contents from outside influences, such as physical damage, while in
transit.
Due to the highly hazardous nature of the Category A samples the packaging
must meet special requirements. The principle of triple packaging applies here, and
the transport containers and outer packaging must meet the criteria defined in the
relevant regulations. Category A must only be transported in packaging that meets
the United  Nations  class  6.2  specifications,  complies  with  Packing  Instruction
P620 and have passed specific tests and with UN specification marking as P620.
This  ensures that  strict  performance criteria  are met;  tests  for compliance with
these criteria include a 9-metre (29.5 feet) drop test, a puncture test, a pressure test
and a stacking test. The packages are labelled to provide information about the
contents  of  the  package,  the  nature  of the hazard and the  packaging standards
applied.
- the delivery address (consignee) and sender’s details (shipper), as well
as  24/7  emergency  contact  details including  named  persons  with
telephone numbers to guarantee safe delivery;
- the proper shipping name and the UN number;
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Fig 1.11 Proper shipping name
- the Infectious Substance label;
Marking and labelling is as follows (see Appendix B):
This  label  is  only  for  Category A.  This  label  must  not  be  used when
shipping Category B.
Fig 1.12 The Infectious Substance label for Category A
UN specification marking for P620 packaging (printed on the box).
Orientation label, Cargo only label, if required (depending on the Net Weight
[kg] of the infectious substance in a P620 box).
The exact details can be found in P620 Packing Instruction
For air transport:
The  primary  receptacle  or  secondary  packaging  must  be  capable  of
withstanding,  without  leakage,  an internal  pressure  of  95  kPa.  The  primary
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receptacle  or  secondary  packaging  must  also  be  capable  of withstanding
temperatures in the range of –40°C to +55°C;
For liquids: the net quantity of infectious substances per one P620 box shall
not exceed 50 ml for transport in cargo space of a passenger aircraft; and must not
contain more than 4 litres (contain multiple primary receptacles totalling more than
4 litres) for transport on a cargo only aircraft;
For solids: the net quantity of infectious substances per one P620 box shall
not exceed 50 g for transport in cargo space of a passenger aircraft, and must not
contain more than 4 kg (even if containing multiple primary receptacles totalling
more than 4 kg) for transport on a cargo only aircraft. This quantity limit doesn‟t
apply for animal parts, organs and whole carcasses.
The  three  triple  packaging  principle  has  to  be  adopted  accordingly  using
appropriate packaging systems;
The  entire  package  must  have  been  tested  and  complies  with  Packing
Instruction P620. For further information on marking and labelling of the Category
A shipment package, see P620 Packing Instruction for UN Nos 2814 and 2900.
Category  B  must  be  transported  in  a  packaging  that  complies  with  the
requirements  of  packing  instruction  P650. The  approval  of  the  box  by  the
government is not required, thus UN specification marking is not required.
Marking is as follows:
- packages should be clearly labelled with the delivery address and sender‟s
details to guarantee safe delivery in time at the correct destination;
- label  with  the  proper  shipping  name  in  letters  at  least  6  mm  high:
“BIOLOGICAL SUBSTANCE, CATEGORY B” (Figure 1.13)
Fig 1.13 UN3373 Mark for category B substances.
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- in addition to the proper shipping name, the mark shown below (UN3373 in
diamond) is used for shipments of Category B substances. The UN3373 mark must
always be visible on the outer packaging. 
Additional requirements do apply as for category A for international shipment
and  air  transport.  One  of  the  main differences  between  P650  and  P620  is  the
reduced drop-test to 1.2 meters (4 feet).
For air transport:
- the  primary  receptacle  or  secondary  packaging  must  be  capable  of
withstanding,  without  leakage,  an internal  pressure  of  95  kPa.  The  primary
receptacle  or  secondary  packaging  must  also  be  capable  of withstanding
temperatures in the range of –40°C to +55°C;
- for  liquids:  no  primary  receptacle  shall  exceed  1  litre  and  the  outer
packaging  must  not  contain  more  than 4  litres  (contain  multiple  primary
receptacles totalling more than 4 litres);
- for  solids:  the  outer  packaging  must  not  contain  more  than  4  kg.  This
restriction doesn‟t apply for animal parts, organs and whole carcasses.
The exact details can be found in P650 Packing Instruction for UN No. 3373
Biological materials for which there is a minimal likelihood that pathogens
are present are not subject to regulation if the specimen is carried in a packaging
which will  prevent  any leakage and which is  marked with the words “Exempt
animal  specimens”,  as  appropriate.  The  triple  packaging  system  must  still  be
applied.
This exemption refers to biological materials that do not contain infectious
substances and are therefore not subject to dangerous goods regulations (such as
class  6.2)  and  any  packaging  requirements,  unless  they  meet the  criteria  for
inclusion in another class (such as class 9).
Note: There may be specific regulations in place in some countries for the
shipment, export or import of nucleic acids.
“Overpack” is the term used when one or more packages are combined to
form  one  unit  and  sent  to  the  same destination  by  a  single  shipper.  When
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refrigerants are used to protect  contents,  the overpacks may comprise insulated
vessels or flasks. Whenever an overpack is used, the required marks and labels
shown on the outer packaging must  be repeated  on the outermost  layer  of  the
overpack,  except  for  the  UN specification  marking on P620.  This  requirement
applies to all infectious substances including Categories A and B. Overpacks are
also required to be marked with the word “overpack”.
Combining different categories of infectious substance in a same overpack is
permissible  however  in  this  case outer  labelling  should  indicate  the  highest
category included in the package.
Refrigerants may be used to stabilise specimens during transport.
Ice, ice packs or dry ice shall be placed outside the secondary receptacle. Wet
ice shall be placed in a leak-proof container; the outer packaging or overpack shall
also be leak-proof. Dry ice (solid carbon dioxide) must not be placed inside the
primary  or  secondary  receptacle  because  of  the  risk of  explosion.  A specially
designed  insulated  packaging  may  be  used  to  contain  dry  ice,  typically  a
polystyrene  or waxed-treated  cardboard  box  to  prevent  leakage  and  maintain
temperature. The packaging must permit the release of carbon dioxide gas if dry
ice is used and the package (the outer packaging or the overpack) shall be marked
“UN 1845” and “Carbon dioxide, solid as coolant” or “Dry ice as coolant” and the
weight of the dry ice in Kilograms should also be indicated on the labelling. The
package must also bear the Class 9 – Miscellaneous hazard label.
The  secondary  receptacle  shall  be  secured  within  the  outer  package  to
maintain the original  orientation of  the inner packages  after  the refrigerant  has
melted or dissipated.
If liquid nitrogen is used as a refrigerant, additional requirements have to be
followed according to the relevant regulations for dangerous goods (Division 2.2,
UN 1977). Information on Dry Shipper is available in p19 of WHO Guidance on
regulations for the transport of infectious substances 2017–2018.
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1.4.2 Packaging, labelling and documentation requirements for infectious
substances in Category B
The triple packaging system continues to apply, including for local surface
transport.  Testing documents  are  not  required,  however.  It  may be  possible  to
source packagings locally rather than finding an authorized supplier, provided that
the  packaging  manufacturer  and  the  shipper  can  comply fully  with  the
requirements of P650 (see Figure 1.14).
As for P620, there is no comprehensive list of suppliers of packagings that
comply with Packing Instruction P650. 
However, an Internet search using a suitable international or national search
engine usually  provides  appropriate  information,  as  well  as  access  to  national
regulations. 
Search  phrases such  as  “UN  packaging”  and  “UN  infectious  substance
packaging” produce extensive results. 
Carriers and forwarding agents should also be able to supply details of local
suppliers or local companies that can provide such information.
To  ensure  correct  preparation  for  transport,  packaging  manufacturers  and
subsequent distributors shall provide clear instructions to the consignor or persons
preparing  packages  (e.g.  patients)  on  how the packaging  should  be  filled  and
closed.
For surface transport there is no maximum quantity per package.
For air transport:
• no primary receptacle shall exceed 1 l (for liquids) or 1 kg (for solids)
• the volume shipped per package shall not exceed 4 l or 4 kg.
Provided all the requirements of P650 are met, there are no other transport
requirements. P650 incorporates all that is needed to make a shipment for Category
B infectious substances.
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Fig 1.14 Example of the triple packaging system for the packing and labelling of
Category B infectious substances 
(Kindly provided by IATA, Montreal, Canada)
Marking
Each package shall display the following information:
• for air: the shipper’s (sender’s, consignor’s) name, address and telephone
number;
• for air: the telephone number of a responsible person, knowledgeable about
the shipment;
• the receiver’s (consignee’s) name, address and telephone number;
• for  air:  the  proper  shipping  name  (“DIAGNOSTIC  SPECIMENS”  or
“CLINICAL SPECIMENS” or “BIOLOGICAL SUBSTANCE, CATEGORY B”);
• temperature storage requirements (optional).
The  marking  shown  in  Figure  1.15 is  used  for  shipments  of  Category  B
infectious substances.
Minimum dimension: the width of the line forming the square shall be at least
2 mm, and the letters and numbers shall be at least 6 mm high. For air transport,
each side of the square shall have a length of at least 50 mm.
43
Colour: none specified, provided the mark is displayed on the external surface
of the outer packaging on a background of contrasting colour and that it is clearly
visible and legible.
For surface transport (by road, rail and sea): no other mark is required.
For air transport: the mark shall be shown but with the following additional
information: The  words  “DIAGNOSTIC  SPECIMENS”  or  “CLINICAL
SPECIMENS” in letters at least 6 mm high shall be displayed adjacent to the mark
From 2007 the name will be “BIOLOGICAL SUBSTANCE, CATEGORY B” for
all modes of transport, but this shipping name can be used immediately without
contravening the regulations.
Fig 1.15 Marking for infectious substances of Category B
"Overpack" is the term used when several packages are combined to form one
unit and sent to the same destination by a single shipper. When refrigerants are
used to protect contents, the overpacks may comprise insulated vessels or flasks.
Whenever an overpack is used, the required marks and labels shown on the outer
packaging  must  be  repeated  on  the  outermost  layer  of  the  overpack.  This
requirement applies to infectious substances in Categories A and B. Overpacks are
also required to be marked with the word “overpack”.
Refrigerants
Refrigerants may be used to stabilize infectious substances in Categories A
and  B  during  transit. Ice  or  dry  ice  shall  be  placed  outside  the  secondary
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receptacle. Wet ice shall be placed in a leak-proof container; the outer packaging
or overpack shall also be leak-proof. Dry ice must not be placed inside the primary
or secondary receptacle because of the risk of explosions. 
Fig 1.16 Requirements for the Packaging and Transportation
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A specially designed insulated packaging may be used to contain dry ice. The
packaging  must  permit  the  release  of  carbon  dioxide gas  if  dry  ice  is  used.
ICAO/IATA Packing Instruction 904 shall be observed.
The  secondary  receptacle  shall  be  secured  within  the  outer  package  to
maintain the original  orientation of  the inner packages after  the refrigerant  has
melted or dissipated. If dry ice is used to ship infectious substances in Category A,
the  details  shall  appear  on  the  shipper’s Declaration  for  Dangerous  Goods.  In
addition, the outermost packaging shall carry the hazard label for dry ice and the
appropriate marking. If dry ice is used to ship infectious substances in Category B,
the package shall  be marked “Carbon dioxide, solid” or “Dry ice” - this is not
considered further in these guidelines.
If liquid nitrogen is used as a refrigerant, special arrangements shall be made
in advance with the carrier. Primary receptacles shall be capable of withstanding
extremely low temperatures, and packaging and documentation requirements for
liquid nitrogen shall be observed. In particular, the outermost packaging shall carry
the  hazard  label  for  liquid  nitrogen.  For  air  transport, the  handling  label  for
cryogenic  liquids  shall  also  be  affixed (see  Figure  6)  –  this  is  not  considered
further in these guidelines.
1.4.3 Documentation
Dangerous  goods  documentation  (including  a  shipper’s  declaration)  is  not
required for Category B infectious substances. The following shipping documents
are required. To be prepared and signed by the shipper (sender, consignor):
• for international shipments: a packing list/proforma invoice that includes the
shipper's and the receiver’s address, the number of packages, detail of contents,
weight, value (Note: the statement “no commercial value” shall appear if the items
are supplied free of charge);
• an import and/or export permit and/or declaration if required.
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Documentation  required  by  a  transporter  or  operator  should  be  accessible
without opening the package.
Packages  for  or  from  overseas  destinations  must  be  accompanied  by  the
necessary documentation, including customs and/or quarantine permits. A check of
the Australian Quarantine and Inspection Service website4 may be necessary to
review the latest relevant information.
When  transporting  dangerous  goods  internationally  under  the  European
Agreement concerning the International Carriage of  Dangerous Goods by Road
(ADR),  you  must  ensure  your  consignments  are  always  accompanied  by  a
transport document. This sets out detailed information on the load being carried,
including full classification of the substance(s) carried and how it is packaged. You
must present the required information in a certain order and follow certain rules on
language.
In addition to documents required under other regulations, under ADR you
must ensure that the following documents are carried on the transport unit:
• transport document(s) containing prescribed information for each dangerous
substance, material or article being carried - eg their UN number, their technical
name in brackets in addition to the name under which they are being shipped;
• emergency instructions in writing;
• means  of  identification,  including  a  photograph  for  each  member  of  the
vehicle crew.
Some exceptions, or 'derogations' from the provisions of ADR are allowed
under  certain  multilateral  agreements.  These  allow  goods  to  be  transported  -
usually  for  a fixed period -  between or  through any of  the countries  that  have
signed up to the multilateral agreement. If you are carrying dangerous goods under
such an agreement, you must carry a copy of that agreement.
You should also check whether other legislation beyond the ADR applies to
the dangerous goods you carry - for example, load restrictions on the carriage of
petrol.
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Before ship dangerous goods,  you need to  properly complete the required
transport documents: the air waybill and the Shipper’s Declaration for Dangerous
Goods.
The main  purpose  of  the  Dangerous  Goods Declaration  (DGD) is  for  the
shipper to provide critical information to the aircraft operator or carrier in a format
that is consistent throughout the transportation industry. This standard is part of the
International  Air  Transport  Association  (IATA)  Dangerous  Goods  Regulations
(DGR).
Section  8  of  the  IATA  DGR  begins  with  the  statement:  “A  Shipper’s
Declaration must be completed by the shipper for each consignment of dangerous
goods.”
There  are  nine  materials  that  have  a  low risk  and are  excepted  from this
requirement. These are:
UN 3164, Articles, pressurized, hydraulic;
UN 3164, Articles, pressurized, pneumatic;
UN 3373, Biological substance, Category B;
UN 1845, Carbon dioxide, solid (Dry ice) when used as a refrigerant for other
than dangerous goods;
Dangerous goods in excepted quantities;
UN  3245,  Genetically  modified  organisms  and  Genetically  modified
microorganisms;
Lithium ion  or  lithium metal  cells  or  batteries  meeting  the  provisions  of
Section II of Packing Instructions 965–970;
UN 2807, Magnetized material; and
Radioactive material, excepted packages.
For each consignment of dangerous goods as defined and regulated by the
DGR, the shipper is required to:
Use only the correct form in the correct manner;
Ensure the information is accurate, easy to identify, legible and durable; and
Ensure that the shipment has been prepared in accordance with the DGR.
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These  requirements  are  essentially  what  the  dangerous  goods  shipper  is
declaring when they complete the IATA Dangerous Goods form and what appears
in bold type in the bottom left-hand corner of the form:
I hereby declare that the contents of this consignment are fully and accurately
described  above  by  the  proper  shipping  name,  and  are  classified,  packaged,
marked,  labelled/placarded,  and  are  in  all  respects  in  proper  condition  for
transport  according  to  applicable  international  and  national  government
regulations. I declare that all of the applicable air transport requirements have
been met.
The Dangerous Goods Declaration must be signed and dated by the shipper.
Other  persons  employed to act  on behalf  of  the  shipper  such as  consolidators,
freight forwarders, and cargo agents may sign the DGD on behalf of the shipper.
Even though the IATA specifies retention of the transport documents for a
minimum of three months, the U.S. Department of Transportation (DOT) requires
24 months. Electronic versions may be used if they can be reproduced in printed
form.
1.5. COVID-19 vaccine specifications and countries which create vaccine
The COVID-19 vaccine is a vaccine that can protect against the COVID-19
coronavirus infection. The development of  a vaccine is a critical  health system
challenge as the disease pandemic began in late 2019. As of September 2020, more
than 200 potential vaccines are being developed by various medical institutions
and  pharmaceutical  companies,  and  human  trials  have  begun  for  40  drugs.
Currently, seven candidate vaccines are in phase III clinical trials, 4 of which are
of Chinese origin.
At  the  end  of  February  2020,  the  World  Health  Organization  (WHO)
announced  the  hope  that  a  vaccine  against  the  SARS-CoV-2  virus  that  causes
COVID-19  will  become  available  in  18  months.  Vaccine  development  is
complicated by the constant mutation of the virus and the difficulty of studying it.
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Its  effectiveness  depends  on  the  ability  to  induce  an  immune  response  in  the
human body and on its safety for it.
Strains  of  the  SARS-CoV-2  virus,  which  causes  a  dangerous  infectious
disease,  COVID-19, were first  detected in December 2019. The genome of the
virus was the first to be completely deciphered by the Chinese health services; on
January 10, it was made publicly available. On January 20, 2020, human-to-human
transmission  was  confirmed  in  Guangdong,  China.  On  January  30,  2020,  in
response to the outbreak, WHO declared an international health emergency, and on
February 28, 2020, WHO raised its global risk assessment from high to very high.
On March 11, 2020, the epidemic was recognized as a disease with signs of a
pandemic.
Many  organizations  are  using  published  genomes  to  develop  possible
vaccines against SARS-CoV-2. About 35 companies and academic institutions are
involved,  three  of  which  receive  support  from  the  Coalition  for  Epidemic
Preparedness  Innovation  (CEPI),  including  projects  from  biotech  companies
Moderna and Inovio Pharmaceuticals, and University of Queensland.
As of March 2020, about 300 studies were in progress. Until April 23, 2020,
83 drugs were included in the WHO list of promising developments, of which 77
are  at  the  stage  of  preclinical  studies  and  six  are  undergoing  clinical  trials  in
humans.
The example of the British pharmaceutical concern AstraZeneca shows the
intense competition between countries in the pursuit of a vaccine. The company
has already developed a promising drug. "In September, we will know if we have
an effective vaccine or not," AstraZeneca chief Pascal Soriot told the BBC.
But already now, many millions of doses of the drug not yet approved for use
have been staked out by the governments of the UK, the United States, the Global
Alliance for  Vaccines and Immunization (GAVI),  as well  as  Germany, France,
Italy and the Netherlands together. But it is not clear who will get this vaccine first,
if it really turns out to be effective.
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Therefore,  the  governments  of  different  countries  are  betting  on  several
promising "horses" at once. And that's the right strategy, says Alexander Nuyken
of the consulting firm EY. “It is still completely unclear who will come first,” he
told DW, “so it’s good that government subsidies are distributed in a wide fan.”
EY analysts believe that of the more than 160 vaccine projects currently underway
in different countries, 97 percent will not be brought to the certification stage.
In the United States, the vaccine race takes on the characteristics of a military
operation.  Leadership  is  entrusted  to  four-star  General  Gustav  Pern,  a  military
logistics specialist and chief of the United States Army Logistics Command. The
general  received  $  10  billion  from  the  Washington  administration  so  that  by
January there would be enough doses in the country to vaccinate all Americans.
The German government went even further - for 300 million euros, it entered
the  share  of  a  potential  vaccine  manufacturer  CureVac,  which was allowed to
conduct clinical trials of its new drug ten days ago. When creating it, the so-called
RNA technology (ribonucleic acid, RNA) was used, in which the vaccine contains
parts of the genetic material of the virus.
CureVac  from  Tübingen,  Germany,  is  among  the  16  companies  that,
according to the WHO, are already officially testing their vaccines in humans. It is
believed that  the German government  spent  the aforementioned 300 million in
order  to  get  ahead  of  foreign  competitors,  who  also  have  their  eyes  on  this
biotechnology company.
The COVID-19 vaccines that scientists around the world are working on are
being  developed  on  different  technology  platforms,  each  with  advantages  and
disadvantages.
Inactivated vaccines are produced by growing SARS-CoV-2 in cell culture,
usually on Vero cells, followed by chemical inactivation of the virus. They can be
produced relatively easily, but their yield can be limited by the productivity of the
virus in cell  culture and the need for  production facilities  with a high level  of
biosafety. These vaccines are usually given intramuscularly and may contain alum
(aluminum hydroxide) or other adjuvants. Since the entire virus is presented to the
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immune system, immune responses are likely to target not only the SARS-CoV-2
spike  protein,  but  also  the  matrix,  envelope  and  nucleoprotein.  Examples  of
inactivated  vaccine  candidates  are  CoronaVac  from Sinovac  Biotech,  vaccines
from  the  Wuhan  and  Beijing  Institutes,  QazCovid-in  Research  Institute  of
Biosafety Problems of Kazakhstan, etc.
Live attenuated vaccines are produced by creating a genetically attenuated
version of the virus that replicates to a limited extent without causing disease but
eliciting  immune  responses  similar  to  those  caused  by  natural  infection.
Attenuation  can  be  achieved  by  adapting  the  virus  to  adverse  conditions  (for
example, growing at a lower temperature, growing in non-human cells) or through
rational modification of the virus (for example, deoptimizing codons or removing
genes responsible for counteracting innate immunity recognition). An important
advantage of  these  vaccines  is  that  they can be administered intranasally,  after
which they induce immune responses in the mucous membranes that can protect
the upper respiratory tract, the main portal of entry for the virus.
In addition, since the virus replicates in the vaccinated individual, the immune
response is likely to affect both structural and non-structural viral proteins through
antibodies and cellular immune responses.  However, the disadvantages of these
vaccines include safety concerns and the need to modify the virus, which is time-
consuming if  carried out using traditional methods, and technical  complexity if
reverse genetics is used. An example of a live attenuated vaccine is the SpyBiotech
Alliance UK and Serum Institute of India candidate vaccine.
Vector,  non-replicating  vaccines represent  a  large  group  of  vaccines  in
development.  Such  vaccines  are  usually  based  on  another  virus  that  has  been
engineered to express the spike protein and has been disabled from replication in
vivo due to the deletion of portions of its genome. Most of these approaches are
based  on  adenoviral  vectors  (AdVs),  although  modified  Ankara  [de]  viruses
(MVA), human parainfluenza virus vectors, influenza virus, adeno-associated virus
and Sendai virus are also used. 
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Most  of  these  vectors  are  injected  intramuscularly,  enter  the  cells  of  the
vaccinated person, and then express a spike protein to which the host's immune
system responds. These approaches have many benefits. There is no need to deal
with live SARS-CoV-2 during production, there is considerable experience in the
production of large quantities of some of these vectors (the primary boost vaccine
based on Ad26-MVA against the Ebola virus was created many years ago), and the
vectors  show  good  stimulation  of  responses  both  B  cells  and  T  cells.  The
disadvantage is that some of these vectors are affected and partially neutralized by
preexisting vector immunity. 
This can be avoided by using vector types that  are either rare in humans,
derived from animal  viruses,  or  by  using viruses  that  do  not  induce  particular
immunity by themselves (eg, adeno-associated viruses). In addition, immunity to
vectors can be problematic when using prime-boost schemes, although this can be
avoided by using priming with one vector and boosting with another. An example
of a non-replicating vector vaccine is the Gam-COVID-Vac of the N.F. Gamaleya
Research  Center  (AdV5  /  AdV26),  CanSino  (AdV5),  Oxford  /  AstraZeneca
ChAdOx1 nCoV-19 (Chimpanzee AdV), GRAd-COV2 (Gorilla AdV), etc.
The vectors that  replicate  usually  come from attenuated  or  vaccine  virus
strains  that  have  been  engineered  to  express  a  transgene,  in  this  case  a  spike
protein.  In  some  cases,  animal  viruses  are  also  used,  which  do  not  replicate
efficiently and do not cause disease in humans. This approach can lead to a more
sustained induction of immunity, since the vector spreads to some extent in the
vaccinated person and often also induces a strong innate immune response. Some
of these vectors can also be injected across mucosal surfaces, which can elicit an
immune response in the latter. 
An example is a vector based on the influenza virus being developed by the
Beijing Institute of Biological Products. vectors based on vesicular stomatitis virus,
equine pox and Newcastle disease virus are currently under development.
Vector, inactivated. Some SARS-CoV-2 vaccine candidates currently under
development are based on viral vectors that display a spike protein on their surface,
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but are  then inactivated before use.  The advantage of  this approach is  that  the
inactivation process makes the vectors safer, as they cannot replicate even in an
immunocompromised host. Using standard viral vectors, it is not easy to control
the amount of antigen that is presented to the immune system, but in vaccines with
inactivated vectors, it can be easily standardized, as in the case of vaccines with
inactivated  or  recombinant  proteins.  These  technologies  are  currently  in  the
preclinical stage.
DNA vaccines are based on plasmid DNA, which can be produced in large
quantities  in  bacteria.  Typically,  these  plasmids  contain  mammalian expression
promoters and a gene encoding a spike protein that is expressed in the vaccinated
individual  upon  delivery.  The  great  advantage  of  these  technologies  is  the
possibility  of  large-scale  production in  E.  coli,  as  well  as  the high stability  of
plasmid DNA. However, DNA vaccines often show low immunogenicity and must
be delivered via delivery devices to be effective. This requirement for  delivery
devices such as electroporators limits their use.
RNA vaccines are relatively recent. Like DNA vaccines, genetic information
about an antigen is delivered in place of the antigen itself, and then the antigen is
expressed in the cells of the vaccinated person. Either mRNA (modified) or self-
replicating RNA can be used. Higher doses are required for mRNA than for self-
replicating RNA, which amplifies itself, and RNA is usually delivered via lipid
nanoparticles. RNA vaccines have shown great promise in recent years, and many
are  under  development,  for  example  against  Zika  virus  or  cytomegalovirus.
Promising preclinical test results have been published as potential vaccines against
SARS-CoV-2.
The  advantages  of  this  technology  are  that  the  vaccine  can  be  produced
entirely in vitro. However, the technology is new and it is not clear what problems
will be faced in terms of large-scale production and long-term storage stability as
ultra-low temperature is required. In addition, these vaccines are given by injection
and are therefore unlikely to induce strong mucosal immunity. An example is the
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vaccine candidate BNT162b2 of the German pharmaceutical concern BioNTech,
the storage temperature of which is -70 ° C.
Recombinant  protein  vaccines can  be  divided  into  recombinant  spike
protein  vaccines,  RBD  (Receptor-binding  domain)  recombinant  vaccines,  and
virus-like particle (VLP) vaccines. These recombinant proteins can be expressed in
a variety of expression systems, including insect cells, mammalian cells, yeast and
plants; it is likely that RBD vaccines can also be expressed in Escherichia coli. The
outputs, as well as the type and degree of post-translational modifications, vary
depending on the expression system. In particular, for recombinant vaccines based
on spiked proteins,  modifications such as deletion of a polybasic cleavage site,
inclusion of  two (or  more)  stabilizing  mutations  and inclusion of  trimerization
domains,  as  well  as  a  purification  method  (soluble  protein  versus  membrane
extraction) - can affect the evoked immune answer. 
The  advantage  of  these  vaccines  is  that  they  can  be  produced  without
handling live virus. In addition, some recombinant protein vaccines, such as the
FluBlok influenza vaccine, have been licensed and have significant manufacturing
experience.  There are also disadvantages.  Spike protein is relatively difficult  to
express  and  this  is  likely  to  affect  productivity  and  how  many  doses  can  be
obtained. RBD is easier to express; however, it is a relatively small protein when
expressed on its own, and although strong neutralizing antibodies bind to RBD, it
lacks the other neutralizing epitopes that are present on the full spine. 
This  could  make  RBD  vaccines  more  susceptible  to  antigenic  drift  than
vaccines  containing  full  length  spike  protein.  Like  inactivated  vaccines,  these
candidates are usually given by injection and are not expected to result in sustained
mucosal immunity. An example of a candidate recombinant protein vaccine - NVX
- CoV2373 from Novavax.
Financial risks of pharmaceutical firms
There  are  also  doubts  about  the  interest  of  the  pharmaceutical  and
biotechnology  firms  themselves  in  international  cooperation.  WHO’s  Act
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Accelerator or GAVI’s Covax platform to bring a vaccine ever invented to the
world and to limit patent rights is unlikely to inspire much enthusiasm.
On the one hand, says Alexander Nuiken of EY, the pharmaceutical industry
is aware of its responsibility, it makes remarkable efforts, but on the other, in the
end,  the  invention  and  production  of  a  vaccine  should  be  profitable  for  such
enterprises. And the financial risk is great, because many enterprises have already
started producing their drugs in the hope that if clinical trials are successful and
they are approved for use, they will be able to quickly start selling their unique
vaccine to different countries of the world.
Large pharmaceutical companies with experience in making vaccines at scale,
including  Johnson  &  Johnson,  AstraZeneca,  and  GlaxoSmithKline  (GSK),  are
forming  alliances  with  biotechnology  companies,  national  governments,  and
universities to accelerate progression to an effective vaccine.
To  combine  financial  and  manufacturing  capabilities  for  a  pandemic
adjuvanted  vaccine  technology,  GSK  joined  with  Sanofi  in  an  uncommon
partnership  of  multinational  companies  to  support  accelerated  vaccine
development.
During a pandemic on the rapid timeline and scale of COVID-19 infections
during  2020,  international  organizations  like  the  WHO  and  CEPI,  vaccine
developers, governments, and industry are evaluating distribution of the eventual
vaccine(s). Individual countries producing a vaccine may be persuaded to favor the
highest  bidder  for  manufacturing or  provide  first-service  to  their  own country.
Experts emphasize that licensed vaccines should be available and affordable for
people at the frontline of healthcare and having the greatest need.
Under their agreement with AstraZeneca, the University of Oxford vaccine
development  team and UK government  agreed that  UK citizens  would not  get
preferential access to a new COVID-19 vaccine developed by the taxpayer-funded
university,  but  rather  consented  to  having  a  licensed  vaccine  distributed
multinationally in cooperation with the WHO. Several companies plan to initially
56
manufacture a  vaccine  at  low cost,  then increase  costs  for  profitability  later  if
annual vaccinations are needed and as countries build stock for future needs.
The WHO and CEPI are developing financial resources and guidelines for
global deployment of several safe, effective COVID-19 vaccines, recognizing the
need is different across countries and population segments.
For example, successful COVID-19 vaccines would likely be allocated first to
healthcare personnel and populations at greatest risk of severe illness and death
from COVID-19 infection, such as the elderly or densely-populated impoverished
people.  The  WHO,  CEPI,  and  GAVI  have  expressed  concerns  that  affluent
countries  should  not  receive  priority  access  to  the  global  supply  of  eventual
COVID-19 vaccines, but rather protecting healthcare personnel and people at high
risk of infection are needed to address public health concerns and reduce economic
impact of the pandemic
1.6. Conclusions for theoretical part
Infectious  substances  in  Category  A  will  not  be  accepted  for  shipment
through postal services. 
Infectious substances in Category B may be shipped by registered air mail,
and the Universal Postal Union recommends the following procedure.
The basic triple packaging system is used with the same requirements as for
other  means of  transport. The address  label  shall  display  the  word “Lettre”  or
“Letter”  and  the  green  Customs  Declaration   WHO/CDS/CSR/LYO/2005.22
Guidance on regulations for the transport of infectious substances. Label for Postal
Mail  is  required  for  international  mailing.  “DIAGNOSTIC  SPECIMENS”,
“CLINICAL SPECIMENS” or “BIOLOGICAL SUBSTANCE, CATEGORY B”
shall be identified with the white diamond label with black letters “UN 3373”.
Local/international restrictions may be in force. Prior contact should therefore
be  made  with  thenational  public  operator  to  ascertain  whether  the  packaged
material will be accepted by the postal service in question.
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Statistical  data  collected  by  a  group  of  central  laboratories  showed  the
efficacy of packaging compliant with P650 and P620 in assuring that infectious
substances  are  transported  without  leakage  and  loss  of materials.  For  the  4.92
million  primary  containers  shipped  in  2003  to  any  of  the  worldwide  regional
offices  of  these  central  laboratories,  just  106  breakages,  0.002%  of  the  total
number, were recorded. Moreover, the leakages that did occur were all contained
by  the  absorbent  material,  and  no  damage  to secondary  containers  or  outer
packagings was reported.
CEPI classifies development stages for vaccines as "exploratory" (planning
and designing a candidate, having no evaluation in vivo), "preclinical" (in vivo
evaluation with preparation for manufacturing a compound to test in humans), or
initiation  of  Phase  I  safety  studies  in  healthy  people. Some 321  total  vaccine
candidates are in development as either confirmed projects in clinical trials or in
early-stage "exploratory" or "preclinical" development, as of September.
Phase I trials test primarily for safety and preliminary dosing in a few dozen
healthy subjects,  while Phase II trials – following success in Phase I – evaluate
immunogenicity, dose levels (efficacy based on biomarkers) and adverse effects of
the candidate vaccine, typically in hundreds of people. 
A Phase I–II trial consists of preliminary safety and immunogenicity testing,
is  typically  randomized,  placebo-controlled,  while  determining  more  precise,
effective doses.
Phase III trials typically involve more participants at multiple sites, include a
control  group,  and  test  effectiveness  of  the  vaccine  to  prevent  the  disease  (an
"interventional"  or  "pivotal"  trial),  while  monitoring  for  adverse  effects  at  the
optimal dose.
Definition of vaccine safety, efficacy, and clinical endpoints in a Phase III
trial  may  vary  between  the  trials  of  different  companies,  such  as  defining the
degree  of  side  effects,  infection  or  amount  of  transmission,  and  whether  the
vaccine prevents moderate or severe COVID-19 infection.
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2.1. Biological materials transportation market analysis
Transportation  of  special  cargo  with  the  participation  of  air  transport  is
currently of great importance both for the transport complexes of the countries and
for the world economy as a whole. Given the relevance of the chosen research
topic, the most noteworthy are the characteristic trends in the markets of air freight
and global freight forwarding.
The main principle of the organization of delivery of special cargo with the
participation of air transport is to ensure the safety of transportation, especially for
the delivery of dangerous goods. Among the problematic issues of ensuring the
safety of delivery of these types of goods should be noted the lack of licensing for
the delivery of special categories of goods, including dangerous goods, and this
also applies to the loading and unloading operations.
Another important principle in organizing the delivery of special cargo with
the participation of air transport is to ensure the quality of delivery, which directly
depends  on  the  set  of  organizational,  economic,  technical  and  technological
measures implemented for this in the airline, TEP, airport and other participants in
the delivery process.
It  is  worth  remembering the effect  of  synergy,  when a  quality  interaction
between the participants in the process can provide a greater effect than a simple
set of actions of these participants. The wide use in production of modern methods
of cargo delivery management, the application of the latest world developments in
the field of computer technology and communications can ensure the efficiency of
delivery in general.
Studies conducted by leading experts in the field of aviation, in particular,
ICAO and IATA, showed that the change in world gross product has a significant
impact on freight traffic, a change in gross product by 1% leads to a change in
traffic by 1.5-2%. Analysis of the dynamics of world trade suggests that there is a
direct relationship between world trade and air freight.
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The increase in demand for air freight has led to an increase in the average
payload capacity of aircraft, an increase in the average flight length and a focus on
the development of jet aircraft, which now form the basis of the world's fleet of
aircraft.  Another  important  point  is  that  today  more  than  half  of  all  cargo  is
transported  in  the  cargo  compartments  of  passenger  and  cargo  aircraft,  and
therefore this is another segment of the freight market. Transportation of cargo in
an important compartment of such aircraft allows to place 5-6, sometimes more,
pallets with cargo. The negative point is the specifics of the formation of freight
and passenger flows, which almost never coincide.
According to Boeing's forecasts for the structure of the cargo fleet in 2031,
the fleet will be based on aircraft with a payload of up to 45 tons (1215 units),
while aircraft with a payload of 45 to 75 tons and more than 75 tons will be 832
and 1151 units. in accordance. Currently, up to 60% of traffic is carried out by
purely cargo aircraft. As for the domestic fleet of cargo aircraft, it should be noted
that  it  is  outdated,  airlines  will  spend  more  money  on  its  maintenance  and
modernization, which is essential due to the new requirements of ICAO.
Volumes of freight traffic on scheduled flights tended to increase (Table 2.1),
but due to the crisis in 1998 and the events of 2001 in the United States there was a
slight decrease in subsequent periods. 
It should also be noted that the growth rate of regular domestic traffic is much
lower than on international scheduled flights.
An analysis of the current situation in the global freight market, published in
the  publications  of  IATA and  Boeing  [145],  shows  that  today  the  market  has
already gone through a recession,  the lower point of  decline has now certainly
passed.
It is necessary to further restore the confidence of freight customers in the
market and ensure the stability of the situation, although this applies not only to the
transportation market, but also to the economy as a whole. High growth rates of
traffic volumes are possible not earlier than the middle of 2015.
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Table 2.1
Worldwide cargo turnover on regular and charter flights
Yeah
Freight ton-kilometers were
performed on regular flights
Freight ton-kilometers on charter
flights were performed
Mln. Annual
growth, %
Mln. Annual
growth, %
2010 156568 3,5 18124 –3,3
2011 162213 3,6 17421 –3,9
2012 169681 4,5 16512 –5,7
2013 174589 2,9 17125 –3,2
2014 168456 –9,6 16345 –9,6
2015 167813 –1,2 16256 –1,3
2016 171213 1,9 17124 2,3
2017 174219 1,1 17232 1,4
2018 181233 2,1 17953 1,2
2019 187235 2,4 18321 2,5
The table is based on ICAO and Boeing data.
An analysis of the current situation in the global freight market, published in
the publications of IATA and Boeing, shows that today the market has already
gone through a recession, the lower point of decline has now certainly passed. It is
necessary to further restore the confidence of freight customers in the market and
ensure  the  stability  of  the  situation,  although  this  applies  not  only  to  the
transportation market, but also to the economy as a whole. High growth rates of
traffic volumes are possible not earlier than the middle of 2015.
The total level of income of air carriers is 12-15%, but there are also carriers
that keep their own profitability at 35-40%. Such a high level of profitability is
achieved  through  the  transportation  of  special  categories  of  goods,  effective
planning of commercial loading and other tools. The actual level of profitability of
airlines from the performance of freight traffic in 2011 was slightly more than 0.4
(the unit  is  the level  of  profitability  from the performance of  freight  traffic  in
1987). Airlines were forced to compensate for this shortfall by reducing the cost of
maintaining  offices  and  operating  aircraft,  as  well  as  to  introduce  innovative
technical and technological solutions into their work.
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The air cargo market is currently divided into the following regional markets -
Europe, Asia-Pacific, North America, Latin America, Africa and the Middle East.
The Asia-Pacific region has developed the most dynamically, there is a positive
trend  in  traffic  in  the  Middle  East  and  North  America,  Europe  has  lost  some
position.
Hong Kong remains the largest cargo airport, despite the fact that the total
tonnage of handled cargo decreased in 2011 by 4.7% to less than 4 million tons.
The three leaders are the airports of Memphis (USA) and Shanghai (China). At
Memphis  Airport,  the  volume  of  handled  international  cargo  increased
significantly, but because it accounted for less than 7% of the total, it affected them
very little.
As for  the expert forecasts  of  the growth of the world freight  market,  the
experts are divided. IATA forecasts an average annual growth of world tonnage of
4.2% over the next 5 years, while the growth of world tonne-mileage is projected
at 4.8% (ACI), 5% (IATA) 5.9% (Airbus), 5.6 % (Boeing).
The role of freight forwarding companies specializing in freight is growing,
today  they  have  an  impact,  according  to  various  estimates,  on  65-75% of  the
market. Recently, companies focused on the provision of agency services, or as
they are called - "virtual airlines", have started to appear on the air freight market.
The tasks of these airlines also include the organization of sales and advertising of
transportation, logistics and documentation.
Another trend is cooperation through non-profit agencies such as Cargo 2000
and Cargo 3000. These agencies unite airlines, forwarding companies, providing
them  with  the  regime  of  the  greatest  assistance  in  the  organization  of
transportation,  standardization,  planning.  The  process  of  connecting  flights  is
actively implemented by a group of airlines, for example, through the first WOW
cargo alliance,  which brought together Lufthansa,  Singapore Airlines,  SAS and
JAL.
Today in the world markets of air cargo transportation of special cargoes, in
addition  to  recognized  airlines,  there  are  so-called  freight  agents.  Increasing
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competition in global transportation markets dictates the need to stand out from the
competition, both through image and global recognition, and through the provision
of a wide range of services with a high level of quality at relatively low prices.
Leading classic airlines are not very interested in providing a full range of
services for the service of special categories of cargo for various reasons, the main
of which is their low profitability when it comes to business diversification. On the
other hand, these airlines do not want to lose the markets for special categories of
cargo and therefore turn to freight agents, various logistics intermediaries, TEP,
which organize the entire process of servicing special cargo, while allowing the
airline to earn on these categories cargo.
Pharmaceutical equipment is an extremely important commodity, accounting
for  4.9%  of  the  structure  of  freight  traffic  from  Europe  to  Asia.  Significant
volumes of air transportation of pharmaceutical  products also take place within
China.  The modern pharmaceutical  industry is extremely powerful and requires
separate phases of research in different places, in some cases the area of collection
of clinical trials and laboratories that analyze them in detail are located on different
continents. 
The process of conducting clinical trials of a drug can take up to 15 years, and
the delivery of clinical trial results to the relevant medical institutions must be in
compliance with very strict rules and regulations
At present,  services for the transportation of perishable products by air are
becoming increasingly available at major airports around the world. Some airports
offer a well-organized system for processing perishable products, in other airports
this system is worse organized or does not have the necessary equipment in full.
Ideally, the number of special cooling chambers at the airport should be slightly
higher than the maximum required for a certain period of time, as the forecast
limits may be exceeded.
In fig. 2.1 shows the percentage of refrigerators in airports around the world.
From  these  data  it  can  be  concluded  that  79%  of  airports  offer  at  least  one
refrigerator, more than 1/5 of the world's airports do not have refrigerators. 54% of
64
airports have 1 to 4 refrigerators, 14% of airports have 5 to 10 refrigerators, and
11% of  airports  have  more  than  10  refrigerators.  Airports  with  more  than  10
cameras are large transit centers where most of all perishable goods are handled.
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Fig. 2.1. Percentage of refrigerators in airports all over the world
In  fig.  2.2 shows  the  percentage  of  the  total  volume  of  all  refrigeration
chambers  at  airports  around  the  world.  Thus,  more  than 30% of  the  available
refrigeration chambers at airports have a volume of up to 100 м3, 10% - from 100
to 500  м3,  another 10% - from 500 to 1000  м3,  20% - from 1000 to 5000  м3,
another 20% - from 5000 to 10000 м3 and only 10% - more than 10000 м3.
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Fig. 2.2. Percentage of total refrigeration at airports worldwide
Concluded that there is an imbalance in the location of specialized facilities at
airports around the world. In some cases, the placement of special refrigeration
equipment is limited by the size of the airport, as well as other factors. In order to
ensure an efficient chain of delivery of perishable goods, some airports establish
partnerships with freight forwarding and logistics companies.
There is no clear trend in the international transportation of medicines, but it
can be argued that in 2010 there was a slight decline compared to 2009. In 2012,
the total volume of medical transportation by air exceeded that of 2009. In general,
this market is affected by the same indicators as other freight markets, but there are
a number of characteristics that are related to the situation of the target consumer
market,  as  well  as  the financial  capacity  of  clinics  and laboratories  around the
world.
In the future, it is necessary to focus on the market of delivery of goods that
have both dangerous and perishable properties. The world pharmacological market
is currently estimated by experts at more than 780-800 billion dollars. USA, at the
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same  time  the  market  for  organic  products  can  be  estimated  at  75-80  billion
dollars.  USA.  This  market  is  very  attractive  for  the  world's  leading  energy
companies.  A wide range of biological sample delivery services are offered by
such recognized leaders in the global freight forwarding market as DHL and TNT.
Extremely interesting is the Clinical Express service offered, in particular, by
TNT. This service applies to all types of clinical products, delivery of dry ice, as
well as delivery of patients, tracking of clinical shipments and advice on customs
clearance  of  such  goods.  The  carrier  provides  all  the  necessary  conditions  for
transport and medical equipment.
It is worth noting that pharmaceutical companies have a significant level of
profitability,  the introduction of  the chemical  on the market  costs  0.8-1 billion
dollars. US, and biotechnology - 1.2 billion dollars. USA. At the same time, these
figures are an order of magnitude higher than those spent on these needs a quarter
of  a  century ago.  Currently,  the CIS countries are increasingly involved in the
supply chain of organic products, including Ukraine, where there is an extensive
medical industry that is able to ensure the timely collection of quality samples of
clinical trials.
This potential is not fully used today, but there are all the prerequisites for an
effective system for collecting and delivering clinical trial results.  A significant
problem in the functioning of the market for the delivery of clinical trial results is
the  bureaucratic  and organizational  difficulties  that  cause  obstacles  at  different
stages of the transport process.
Analyzing  the  research  conducted  in  on  the  work  of  pharmaceutical  and
medical-biological enterprises, it should be emphasized that most of the business
processes they implement their own efforts, at the same time, they provide storage
and transportation in more than a third of  cases external  service to specialized
forwarding companies (Fig. 2.3).
This  situation  is  due  to  the  complexity  of  the  delivery  process  for  this
category of goods. In the process of organizing and delivering such goods involved
manufacturers  (factories,  hospitals,  clinics),  manufacturers  and  distributors  of
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containers,  packaging,  refrigerants,  carriers  of  various  modes  of  transport,
companies engaged in the provision of transport and warehousing services, PL-
providers and TEP.
 
  % works in the supply chain, outsourced 
Global Level Region Level Local Level Geographical organization of supply 
chain functions 
Tool          Development of new products 
Implementation.     Leading Exp Center 
                            within the supply chain 
Deliveries             Processing department 
                                        customer orders 
                                   Warehouse storage 
              Incoming and outgoing logistics 
Production.     Production and assembly 
                                                      Service 
Sources                          Strategic bougth 
                         Operational procurement 
Planning                  Demand planning & 
                                                        S&OP 
0 18 36 55 
Fig. 2.3 Organizational model of pharmaceutical enterprises and medical and
biological industry зроби красивий рисунок
A multi-stage distribution and transportation scheme complicates the process
of  delivery  of  pharmaceutical  and  medical-biological  products.  Increasing  the
number  of  intermediaries  and participants  in  the delivery process  increases  the
impact of external factors on the cargo (transshipment, transportation by several
modes of transport, weather and climatic conditions.
Another factor complicating the delivery process is the lack of specialized
service providers (vehicles, containers, warehouses, refrigeration equipment) that
have passed the relevant certification and can provide services of the appropriate
level  of  quality.  Domestic  providers  are  not  yet  able  to  provide  them  at  the
appropriate level. The use of the services of European providers increases transport
costs.
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According to experts, since 2009, international players have begun to actively
explore the Ukrainian market of delivery of pharmaceutical and medical-biological
products. The implementation of a full cycle of service delivery of such goods has
necessitated  the  implementation  of  the  process  of  customs  clearance  and
organization  of  consolidation  and  deconsolidation  works  in  commercial
warehouses and terminals.
There are few companies that provide a full cycle of service for such goods,
as providing a full range of services is an extremely difficult task. The possibility
of this exists only in companies with significant volumes of traffic. Currently, in
the  market  of  delivery  of  pharmaceutical  and  medical-biological  products  in
Ukraine, the leading role is played by three major players that control almost 75%
of the market. The position of these companies is dominant and the opportunities
for new large companies to enter the market are significantly limited.
The  Ukrainian  market  for  pharmaceutical  and  medical-biological  products
tends to grow due to the increase in the number of drugs that require temperature
control,  as  well  as  due to  the significant  interest  of  foreign laboratories  in  the
results of clinical trials from Ukraine.
In  today's  market  of  freight  forwarding  and  logistics  services,  there  are
several factors that complicate the process of organizing delivery and reduce its
efficiency. The first is the contradiction and unregulated regulatory framework. If
the regulations define the requirements for transportation and storage of vaccines,
there  is  no  similar  mechanism  for  biotechnological  products  that  require
temperatures from +2 to +8 ,C. Therefore, security of supply issues throughout the
chain  are  not  supported  by  legal  requirements.  The  second  factor  is  the
underdeveloped transport infrastructure, which does not allow the use of optimal
transport solutions and leads to increased transport costs.
According  to  a  report  by  the  European  Federation  of  Pharmaceutical
Industries  and  Associations,  the  pharmaceutical  industry  is  one  of  the  world's
leading high-tech industries in terms of profitability and the use of innovation. In
general, the processes of implementing innovative products in the pharmaceutical
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industry take years and sometimes decades. Moreover, according to the results of
clinical  trials,  only  0.01–0.02%  of  all  substances  eventually  enter  the
pharmaceutical market.
It is also necessary to analyze in detail the reasons for the differences in the
efficiency of the supply chain between leaders and lagging companies, which were
identified by PwC experts in. The operating profit of these companies is explained
by the fact  that  the leading companies have better  opportunities  in the market,
namely large customers, use more advanced technologies for organizing work and
managing their own profitability.
The  difference  in  delivery  timeliness  between  leading  and  lagging
pharmaceutical companies is much smaller at 21%. However, it should be noted
that disruption of delivery of even a single batch of pharmaceutical products can
have catastrophic consequences for the supplier and lead to complete loss of cargo,
and therefore significantly affect the profitability of the company.
Among the most  important  factors  in  the  supply chain for  pharmaceutical
companies  are:  cost  minimization,  maximizing  supply  efficiency,  complexity
management, maximizing supply flexibility and minimizing risks (Figure 2.4). 
Fig. 2.4 The most important factors in the supply chain for pharmaceutical
companies
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Therefore,  there  is  a  problem  in  the  simultaneous  consideration  of  many
criteria in the delivery of products of the pharmaceutical and medical-biological
industries.
Ukraine  International  Airlines  (UIA)  was  founded  in  1992  through  the
establishment of a subsidiary Air Ukraine International. Airline has been assigned
rights to implement flights to Western Europe. The first flight was made on the
route Kiev-London-Kiev on November 25, 1992. After the suspension of flights by
Aerosvit airline, UIA act as a national carrier of Ukraine. Meanwhile, UIA succeed
to obtain a connection on most routes, which were previously provided by Aerosvit
airline.100% of UIA is privately owned. 
The main activity of the airline is the performance of passenger and freight
transportation. UIA’s  fleet  consists  of  33 modern aircrafts:  4  long-haul  Boeing
767-300ER,  14  medium-haul  New  Generation  Boeing  737,  10  medium-haul
classical  Boeing  737  (including  one  freighter  737-300SF),  and  5  medium-haul
Еmbraer-190.  The  main  base  airport  of  UIA is  the  State  International  Airport
Borispol. 
The most important priority for the UIA today is safety standards that must
correspond and meet high international standards. UIA were the first airline on the
territory  of  CIS  countries  that  received  a  certificate  IOSA  (International
Operational  Safety  Audit)  and  became  an  international  registry  as  IATA
(International Association of air transport). 
 In  2011,  the  airline  has  once  again  successfully  passed  inspection  for
compliance with the requirements of modern operational safety and received their
next fourth "certificate" as a reliable provider of IOSA. In May 2014 it is entered
into  force  new requirements  for  regulation  EU 452/2014  for  the  authorization
procedures and security monitoring of aircrafts of operators from third countries
(Third Country Operators) that are flying into European airports. 
A  single  certificate  Third  Country  Operators  authorization  replaces  all
previously  issued  documents  by  every  European  country  for  UIA  and  allows
airline to fly in the airspace of the European Union and the four countries of the
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European  Free  Trade  Association  -  Iceland,  Liechtenstein,  Norway  and
Switzerland. 
This event was followed by another confirmation of the UIA’s high level of
aviation safety and adherence to operational, which fully meet international ones.
Therefore, UIA can be described as:
- Airline actually acts as a monopolist on Ukrainian market by offering the
largest number of European destinations from Ukraine than any other airline;
- A modern air carrier that has its network, which enables to connect major
cities in Ukraine, and Ukraine with all major cities in Europe, CIS, Asia, the Arab
Gulf and the US;
- Reliable airline, which is continually expanding its geography, thanks to
agreements with leading aviation companies from all over the world.
Fleet of UIA contains aircraft types from two manufactures, represented by
Boeing and Embraer.  All  the diagrams presented above are taken for  the May
2016. Average fleet age is 14.9 years. 
The share of the frequency of utilization of Boeing aircraft is 75,8%, while
the utilization of Embraer aircraft is 24,2%. The seat capacity is higher in Boeing
aircrafts  that  makes  81,5%,  while  seat  kilometres  represents  86,4  compare  to
13,8% in Embraer aircraft (Figure 2.5). 
On  April  2,  2016  it  was  introduces  new  Boeing  aircrafts  scheduled  for
transportation. UIA fleet replenishment in early summer season is very justified,
since the summer of 2016 year UIA is expanding its route network and increasing
frequency on many popular destinations. 
The first two aircraft already in service, and the next two Boeing 737-800
aircraft are scheduled to enter service in early May 2016. Additionally, in 2016,
UIA is considering to lease 4 more aircraft.
As  at  28  May  20  16  the  airline's  fleet  consists  of  33  aircraft  of  various
modifications.
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Fig.2.5 Aircraft manufacturer for UIA’s fleet
According the aircraft type UIA use mainly four types of aircrafts:
Boeing 737 Freighter 
Boeing 737 Passenger 
Boeing 767 Passenger 
Embraer 170/190
Different modifications (Figure 2.2) are possible depending on the demand of
transportation  and  optimization  criteria.  It  is  important  to  consider  all  major
characteristics of presented aircrafts, while it directly influences on transportation
as the aircrafts are the main resource that airline has.
Table 2.2
Fleet of UIA
Aircraft type Max.  cruising
speed
Seating
capacity
Max.  range
approx.
Quantity
Boeing 767-300ER 850 km/h up to 261 11,070 km 4
Boeing 737-300 880 km/h up to 135 5,000 km 3
Boeing 737-500 880 km/h up to 112 5,000 km 6
Boeing 737-800 940 km/h up to 186 6,000 km 10
Boeing 737-900 970 km/h up  to
189/215
6,000 km 4
Embraer-190 890 km up to 104 3,300 km 5
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Fig.2.6 Aircrafts’ modifications
Boeing 737-800 as an aircraft  subtype is  mostly used on UIA flights.  All
parameters,  such  as  frequency  of  operations,  seat  capacity  and  available  seat
kilometres are higher than in other aircraft subtypes used, representing 27%, 28,3%
and 31,2% accordingly.
Meanwhile, for example such an aircraft which provide also the high level of
available  seat  kilometres  is  not  used  frequently,  as  Boeing  767  passenger
modification.
To note, fleet the airline "International Airlines of Ukraine" consists mainly of
aircraft  from Boeing  (Figure  2.3),  the  company  which  is  known  for  its  good
attitude  towards  the  environment,  and  which  embodies  a  number  of  advanced
technologies.
Modern aircraft company Boeing can produce much less noise compare to 30
years ago - on average by 75%. The noise level of modern aircraft is regulated by
the International Civil Aviation Organization (ICAO). Aircrafts Boeing-737 and
Boeing-767  comply  with  the  standards  of  International  Civil  Aviation
Organization,  Section  3,  on  noise  levels,  as  well  as  the  basic  requirements  of
emissions. 
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Fig.2.7 Aircraft subtype for UIA’s fleet
The majority of flights is realised with narrow body aircrafts, which consist of
96% of operations. This type of aircraft is used for short and medium haul flights.
Wide  body  aircrafts  are  used  for  the  long  haul  flights  and  the  available  seat
kilometres represent 26,1% in May 2019. 
Fig.2.8 Aircraft category for UIA’s fleet
The majority of flights is realised with narrow body aircrafts (Figure 2.8)
UIA provides different cabin classes for its passengers on all flights. Mainly,
the majority of passengers travel in economy class (88,5%), in business class there 
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is around 11% of passengers and premium economy was chosen just by 1,4% of
UIA’s passengers (Figure 2.9).
Fig.2.9 Cabin class for UIA’s fleet
Wizz Air, legally incorporated as Wizz Air Hungary Ltd. (Hungarian: Wizz
Air Hungary Légiközlekedési Kft.) and stylised as W!ZZ Air, is a European ultra
low-cost airline with its head office in Budapest. The airline serves many cities
across Europe, as well as some destinations in North Africa and the Middle East. It
has the largest fleet of any Hungarian airline, although it is not a flag carrier, and
currently serves 44 countries. 
Its  Jersey-based  parent  company,  Wizz  Air  Holdings  plc,  is  listed  on the
London Stock Exchange and is a constituent of the FTSE 250 Index. As of 2020,
the  airline  has  its  largest  base  at  Budapest  Airport  and Luton Airport  with  70
destinations. In 2019 the airline transported 39.8 million passengers.
The airline was established in September 2003. The lead investor is Indigo
Partners,  an  American  private  equity  firm  specialising  in  transportation
investments. The first flight was made from Katowice International Airport on 19
May 2004. The airline's CEO is József Váradi, former CEO of Malév Hungarian
Airlines. The company is registered in Pest County (Hungary).
On 25 February 2015, Wizz Air started trading on London Stock Exchange.
In November 2017, Wizz Air announced that they were planning to launch a
British division called Wizz Air UK. The airline is based at London Luton, mainly
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to take advantage of a number of take-off and landing slots acquired from Monarch
Airlines when the latter entered administration in 2017.
The  airline  applied  successfully  to  the  CAA for  an  AOC and  a  Type  A
Operating Licence. The airline launched operations in March 2018 using British
registered aircraft. Wizz Air UK will start to take over the flights to the UK that
are currently operated by Wizz Air. Wizz Air said that the airline will employ up to
100 staff by the end of 2018.
In November 2018, it was reported that Wizz Air had announced plans to
reactivate its Wizz Air Ukraine subsidiary, approximately three years after it was
shut down. Under the plan, Wizz Air Ukraine will seek to complete certification in
2019  following  the  acquisition  of  twenty  A320/321  neo  jets.  Bases  will  be
developed in Kyiv as well as other cities across the country. By 2025, it aims to
have a passenger throughput of 6 million passengers per annum.
In July 2020, the airline announced that it will form a joint venture with the
Abu  Dhabi  Developmental  Holding  Company.  In  October  2020  the  airline
announced that its first Scandinavian base would be opened at Oslo's Gardermoen
Airport  in  November  2020:  the  two aircraft  based  there  would  also  undertake
domestic flights within Norway.
Wizz Air dismissed concerns about the damage the airline may be causing to
the environment, raised by the "flightshame" movement. This dismissal was based
on the airline's per-passenger emission level. 
The company said that it would reduce emissions per capita by an additional
30 percent by 2030.
At  the  same  time,  Wizz  Air  condemned  inefficient  airlines  -  such  as
Lufthansa - offering business class and using outdated technologies, which cause
far more specific environmental damage than Wizz Air.
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Fig 2.10 Wizz Air fleet
2.2. General characteristics of the selected airline
The  environment  of  the  organization  is  characterized  by  diversity,
complexity, constant change and in general is unstable. This circumstance, along
with  the  unpredictability  of  the  behavior  of  staff  and  managers  and  gives  the
activities of the organization, especially in the future, an element of uncertainty.
Wizz Air operates regular services and any organization is an open system. A
sign of the modern organization is resilience, ie the ability to function and develop
in  conditions  external  and  internal  influences,  outrageous,  while  maintaining
balance use a business model that is characterized by features: the main activity is
the transportation of passengers and goods; a large network of routes; availability
of own pricing policy; complex implementation system through global systems;
availability of an agency network for product sales on the market; large fleet of
aircraft; in-house maintenance of aircraft.
Compared  to  previous  years,  the  airline  is  increasing  its  capacity  and
expanding its services in new territories. Thus, according to the company's official
website, the official profit for 2019 amounted to more than 1,700 million euros.
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Wizz Air has vertical connections due to the presence of departments with a
manager at the top of each. This structure makes it easier to organize the workflow.
But  linear  systems  are  also  available.  Wizz  Air  uses  a  mixed  organizational
structure.
The airline plans to operate more than 160 aircraft in 5-7 years. Wizz Air
aircraft  are  easily  visible  at  airports  because  of  their  colors  -  white,  pink  and
purple.
Wizz  Air  Ukraine  started  operating  in  2008.  On March  26,  2015,  it  was
announced that the Ukrainian branch of the company would be liquidated. But on
April 10 it was announced that the company will  remain. There were 4 Airbus
A320-232s with a capacity of 180 people in Ukraine as of 2010. As of January
2016, the activities of the Ukrainian branch have not been resumed, flights are
operated directly by the main company - Wizz Air.
Maintenance is provided by Lufthansa Technik and SAS Technical Services.
The increase in the fleet is a planned stage in the airline's development of
transportation  on  already  mastered  routes.  This  will  optimize  the  docking
domestic, medium-haul and transatlantic flights, as well as from 2019, it is planned
to attract Airbus A321Neo, which accommodates 239 passengers.
Thus, the system is characterized by the presence of goals. For anyone the
company's main and overall goal is to survive in the market as long as possible. Of
course, profit, combined with the creation of new ones markets with the help of
new customers are gaining, is an essential feature as well.
The success of the enterprise in a market economy is closely linked to the
right and prudent chosen mission. Because organizations are open systems, they
can only exist when they satisfy some need outside the system. Thus, the task of
transport companies and airlines,  in particular,  are to meet customer needs in a
timely and quality manner transportation.
In  a  market  economy,  the  strategy  of  air  transport  management  can  be
formulated  as  maximizing  profits  from  the  performance  of  air  transportation
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through  the  use  of  modern  marketing  principles,  economic  and  mathematical
methods and models, and so on.
Successful  solution  of  these  problems  is  impossible  without  the  use  of
information and analytical systems. The goal tree method is the main universal
method of systems analysis.
They  have  taken  various  initiatives  during  the  COVID-19  pandemic  to
safeguard  the  Company’s  cost  position  and excellent  balance  sheet  with  €1.5
billion of cash, one of the strongest in the airline industry. We remain focused on
best servicing  our  markets,  while  protecting  the  health  of  customers  and
employees.  Their new health and safety protocol is designed to ensure that  their
customers and crew can fly safely during this unprecedented time for the global
aviation industry.
In addition,  they are taking advantage of  arising market  opportunities  and
have recently announced the expansion of our network with new bases in Albania,
Cyprus, Italy and Ukraine, with more exciting developments to come.  They are
confident that we can ramp up operations quickly, re-stimulate demand with our
ultra-low fares and contribute to the vital recovery of travel and tourism in our
markets.
The  airline  industry  is  facing  unprecedented  times  and  challenges  due  to
COVID-19 but the performance of Wizz Air in 2020 provides a strong foundation
to  underpin  the  business.  Wizz  Air  once  again  delivered an  outstanding
performance against a challenging backdrop in 2020: passenger numbers grew by
15.8 per cent to 40 million, with revenues up 19.1 per cent and a statutory net
profit of €281.1 million.
The Company maintained its  position  as  the  lowest  cost,  lowest  emission
airline  in  Europe  and  the  leading player  in  the  growing  Central  and  Eastern
European  market.  Wizz  Air’s  financial  resilience  to  the  current volatile
environment,  resulting  from  our  focus  and  discipline  on  cost  and  cash
management, stands in stark contrast to the fragility of the vast majority of airlines
operating  in  Europe today.  This  financial  strength,  as evidenced by our  strong
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balance sheet, together with the strength of the entire Wizz Air team, makes Wizz
Air uniquely positioned to take advantage of a market that will continue to show
exciting growth opportunities as and when demand for air travel returns.
Wizz  Air’s  strategy  has  remained  constant  throughout  our  16  years  of
operation.  They deliver  high-quality customer  experience  at  the  lowest  cost,
deploying a highly efficient fleet and ensuring that we meet the highest safety,
operational  and environmental  standards.  With a future order book of 268 new
aircraft,  they are confident in thei ability that  they can further improve customer
experience and increase both the diversity of our network and operational and cost
competitiveness whilst reducing our carbon footprint by a further 33 per cent by
2030.
In addition to the above, in April  2020, Wizz Air was deemed an eligible
issuer under the UK Government's COVID Corporate Financing Facility (CCFF)
and raised £300 million, which further strengthens the Company’s already strong
balance sheet.
In the past financial year, Wizz Air continued to successfully stimulate traffic
and increase passenger numbers by 15.8 per cent to 40 million at a load factor of
93.6 per cent (an increase of 0.9 percentage points). They remained the undisputed
market leader in the CEE region, with a market share of 39.6 per cent in the low-
cost sector and 17.5 per cent of the total CEE market, up from 16.3 per cent last
year. During FY 2020,  they launched 98 new routes and now operate from 25
bases which connect 155 destinations in 45 countries. They remain confident in the
potential of the region and are taking advantage of valuable market opportunities in
and beyond CEE.
Wizz Air new base in Krakow opened in May 2019 with two based Airbus
A321 aircraft. In addition, they started operations to two new destinations in CEE
(Kazan in Russia and Odessa in Ukraine), as well as to seven new destinations
across Western Europe and the Middle East.
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2.3. Production indicators analysis of the selected airline
Wizz Air operates flights in 75 countries: scheduled flights are operated in 59
countries while charter flights in 12 countries. Regular flights are operated on 67
routes, charter - on 30. On average across the year Wizz Air performs about 800
flights per week. To note, about 73% of passengers on Wizz Air flights and 27%
for cargo.
At the same time the number of  people who travelled abroad is still  high
regarding the total  population of  country.  Meanwhile,  one of  the most  popular
foreign destination countries is Poland, where Ukrainians prefer to travel by bus
due to the lower cost of transportation. For instance, Turkey remains one of the
most  popular  destinations  for  Ukrainians  and  majority  prefer  to  travel  by  air
transport.  At the same time, air carriers should understand that nowadays it is the
century  of  competition and air  transport  can  compete  not  just  among different
carriers,  but  as  well  with  other  modes  of  transport.  Wizz  Air have  a  strong
competition with trains and buses in Ukraine and by choosing new strategy for its
development can find new demand for air transportation.
Fig.2.11 Cargo flights and passanger flight ratio
For the number of passengers transported by  Wizz Air, we can observe the
similar rise from 8.1 million in 2015 to 17,8 million in 2020. Therefore, we can
state that the average seat occupancy has also risen. At the same time,  Wizz Air
has not shown a steady growth along all this period. For example, there was a
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significant drop in 2018 due to the political conflicts and economic crisis on the
territory of Ukraine. The drop accounted 37% in comparison to the previous year.
Table 2.3
Passengers’ transportation by Wizz Air
Year
The number
of flights
operated
The number of
pasengers
transported
The change to
previous year (%)
The average seat
occupancy by
passengers (%)
2014 111544 11500000 - 68,5
2015 128560 11900000 26,67 70,1
2016 221180 11800000 -5,26 72
2017 251116 12800000 55,56 75,8
2018 282180 14600000 64,29 78
2019 303471 13800000 -17,39 80,4
2020 391081 17800000 26,32 82,98
It is strongly believed that there is a correlation between the GDP growth and
passenger traffic. It is connected with the effect of affordability of air travel among
the population and the existing demand that is formed due to that. 
Aviation market greatly depends on the economy of state. In conditions of
stabilizing inflation, it is believed  that it is possible to estimate future growth of air
transportation market, focusing on the predicted values of Ukrainian nominal GDP.
GDP  at  current  prices  and  the  basic  parameters  of  the air  transportation
market have historically high correlation. There is a principle of assessment of air
flows: the correlation with GDP growth.  That  is,  1% of GDP growth gives an
average of 1% growth in the airline industry.
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2.4. Financial performance analysis of the selected aircarrier
Economics factors include both national and global trends that can influence
on the demand. Demand for air transportation services has always very closely
interconnected  with  income  growth.  While  income  or  gross  domestic  product
(GDP) rises, passenger and cargo traffic increase and inverse. IHS Economics is
forecasting GDP to grow at 3.1 percent over the next 20 years. Regional variations
are prevalent, with emerging regions growing above world trend and more mature
economies growing below world trend (Figure 2.12).
Based on the expected growth in GDP, airline passenger traffic is projected to
grow at 6.5 percent and air cargo traffic at 4.4 percent (Figure 2.13, Figure 2.14).
As with the economy, world traffic varies by market (Figure 2.15). 
Over the next two decades, fast growth in China’s domestic market will make
it the largest domestic market in the world and traffic within Asia is set to become
the largest travel market.
Fig. 2.12. Emerging markets are driving growth
As a consequence of is low unit cost, Wizz Air is able to price its fares below
almost all of its competitors, while remaining profitable, and thus to drive demand
and  market  share.  This  allowed  Wizz  Air  to  grow  passenger  numbers  at  a
compound average growth rate of 31% pa in the ten years to FY2018.
As noted above, only Pegasus and Ryanair are in the same bracket as Wizz
Air with respect to unit cost. 
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Pegasus operates almost entirely in different markets, although Ryanair has a
significant overlap with Wizz Air (see Threats below). Wizz Air also generates a
high level of ancillary revenue and uses this to keep its basic prices low.
Fig. 2.13. PKP Annual Growth Rate
Fig. 2.14. FTK Annual Growth Rate
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Fig. 2.15. World traffic varies by market
Other  important  economic  factors  which influence the airline’s  ability  to
operate efficiently and passenger’s ability to afford travel are cost factors. These
include air fares which dropped significantly due to deregulation of an industry and
more efficient operations. One of the main components of air fare is a fuel, the
price of which is remaining uncertain and will raise significantly in coming years.
Trends in social  factors  will  have widespread consequences  for  airline
marketing, such as population and demography (age, household, occupation) and
cultural factors (attitudes, preferences, values, beliefs, religion and lifestyle) [33].
• Demand
Air transportation is becoming more affordable and safer mode of transport
• Lifestyle
Passengers demanding enhanced travel experience: faster, more efficient and
seamless service, both at the airport and beyond it;
• The ageing population 
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The product that  is  offered by airports should evolve with more provision
being made for disabled passengers and those needing help at airport, medical care
services. In addition, advertisement should not be primarily focused on fun-loving
young people.
• Changing family structures
There  are  very  important  sub-segments  to  the  market  (singles,  gays,  one-
parent families) whose particular requirement should be taken into account.
• The number of female business travelers increases.
• Shifting  labor  flows  and  a  weakening  of  links  related  to  historic
emigration patterns. 
These are causing a shift in the key markets related to visiting friends and
relatives.
• Passenger travel preferences.
The  passengers,  particularly  those  who  travel  a  lot,  are  becoming  more
demanding in relation to service.
• The population is becoming more environmentally friendly.
The airlines should make a special ecological program, while the construction
of a new airport can be banned due to pollution constrains. At the same time, the
residents of near-airport area can complain because of noise and pollution, which
can be a threat for an airport. 
Technological Factors
The technologies are the fastest changing features of the macro-environment. 
In order to handle passengers and to increase the quality of service, aviation
industry should focus on the use of advanced information technologies designed to
simplify the work of employees of airlines and airports, make the service faster and
less expensive. 
It  can  be  created  competent  infrastructure  by  applying  the  latest  IT
technologies at the airport and airline: from automated surveillance systems that
allow dispatchers to monitor the airspace to the baggage control systems that make
suitcases delivered to the right destination points.
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Self-registration  via  the  Internet  along  with  general  use  self-registration
kiosks  gives  an  opportunity  to  reduce  airport  congestion  and  increase  the
satisfaction of passengers from traveling. These technologies facilitate the passage
of passengers at the airport’s formal procedures and relieve the stress associated
with queues, which is now extremely important as there is a tendency of constant
increase  in  passenger  traffic.  In  addition,  SITA’s  passenger  self-service  survey
demonstrates the high levels of demand among the passenger.
Investments in the development of information technology in airports across
the globe in 2015 will be about USD 6 billion, according to a research made by
SITA (Société Internationale de Télécommunications Aéronautiques). According
to the 10th annual review of the company SITA, conducted with the support of the
Airports  Council  International  and  the  magazine  Airline  Business,  technology
development of passenger service is a top priority for airports worldwide. Airports
also invest in technology in the field of passenger transportation organization and
in the sphere of information services. 
Advanced  information  technologies  are  becoming  a  major  competitive
advantage for airlines and airports serving major transportation hubs. They enable
to manage resources more effectively, improve the quality and reduce the time of
service, provide an acceptable level of expenses and with their help to establish
and maintain standards in civil aviation. 
Environmental Factors
Environmental  factors  have  always  been  a  key  feature  of  the  marketing
macro-  environment  but  have  received  a  greater  profile  recently  as  nowadays
government  and  companies  have  paid  more  attention  to  environmental
sustainability, to a factors as global warming, pollution control, waste disposal and
conservation of energy and other scarce and natural resources.
Airport operations involve a range of activities that affect the environment,
including
• the operation of aircraft;
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• the operation of airport and passenger vehicles, and airport ground service
equipment (GSE);
• cleaning and maintenance of aircraft, GSE, and motor vehicles;
• deicing and anti-icing of aircraft and airfields;
• fueling and fuel storage of aircraft and vehicles;
• airport facility operations and maintenance; 
• construction.
The aviation industry recommends that, as part of a comprehensive approach
to address air transport’s climate impacts, a single global market-based measure
(MBM) be agreed (Figure 2.16). This must be seen as part of a broader package of
measures including new technology, more efficient operations and better use of
infrastructure.
The industry believes that a simple carbon offsetting scheme would be the
quickest to implement, the easiest to administer and the most cost-efficient.
Fig. 2.16. Mapping out the industry commitment.
The industry will have to demonstrate that it is investing as heavily as it can
in the technological development which will increase the efficiency of aircraft and
airports.
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2.5 Wizz Air SWOT analysis
SWOT analysis (or SWOT matrix) is a strategic planning technique used to
help a person or  organization identify strengths,  weaknesses,  opportunities,  and
threats related to business competition or project planning.
This  technique,  which operates by 'peeling back layers  of  the company is
designed for use in the preliminary stages of decision-making processes and can be
used as a tool for evaluation of the strategic position of organizations of many
kinds (for-profit enterprises, local and national governments, NGOs, etc.).
It is intended to specify the objectives of the business venture or project and
identify  the  internal  and external  factors  that  are  favorable  and unfavorable  to
achieving those objectives. 
Fig 2.17 SWOT analysis of Wizz Air
Users  of  a  SWOT  analysis  often  ask  and  answer  questions  to  generate
meaningful information for each category to make the tool useful and identify their
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competitive advantage.  SWOT has  been described as  the tried-and-true tool  of
strategic analysis, but has also been criticized for its limitations.
Wizz Air operates only new, best-in-class aircraft, the Airbus A-320, which it
orders directly from Airbus, and is serviced by the most recognized and reputable
companies, such as Lufthansa Technik and SAS Technical Services.
Fuel supplier:  UkrTATnafta. However, the possibility of changing the fuel
supplier for the company is currently being considered.
SWOT assumes that strengths and weaknesses are frequently internal, while
opportunities and threats are more commonly external. The name is an acronym
for the four parameters the technique examines:
Strengths: characteristics of the business or project that give it an advantage
over others.
Weaknesses: characteristics  that  place  the  business  or  project  at  a
disadvantage relative to others.
Opportunities: elements in the environment that the business or project could
exploit to its advantage.
Threats: elements in the environment that could cause trouble for the business
or project.
Internal factors are viewed as strengths or weaknesses depending upon their
effect on the organization's objectives.
What  may  represent  strengths  with  respect  to  one  objective  may  be
weaknesses  (distractions,  competition)  for  another  objective.  The  factors  may
include personnel,  finance,  manufacturing capabilities,  and all  of  the marketing
mix's 4Ps.
External factors include macroeconomics, technological change, legislation,
and sociocultural changes, as well as changes in the marketplace. Results are often
presented in the form of a matrix.
SWOT analysis is a method of categorization for which lists are compiled,
uncritically  and  without  prioritization,  rather  than  seeking  important  factors  to
achieving objectives; weak opportunities may appear to balance strong threats.
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Competitive forces analysis
The following analysis is based on Michael Porter 5 Forces Model that gives
a more precise  idea of  the positioning in  the airline worldwide where Ukraine
International  Airlines  can  defend  itself  against  or  influence  competitive  forces
(Figure 2.18).
Fig. 2.18 The five forces framework
As  aforementioned,  governments  play  an  important  role  and  it  is  thus
understandable that the Singapore’s state is in the capital structure of the airport
and has an interest to develop and promote the airline activity by investing costs in
it. Generally, competition does not exist on the national market but is very present
outside. 
A high degree of rivalry will usually compromise the potential profitability of
an  industry  and  will  typically  result  in  innovation,  which  stimulates  consumer
demand for the products of the industry.
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Threat of new entrants
The  airline  industry  is  a  capital-intensive  utilizing  enormous  range  of
expensive equipment and facilities. In order to set up an airline companies need to
have either good credit rating to lease some planes or the capital to buy them. So
the initial cost of entry is high. Additionally, a potential entrant also needs working
capital  to  absorb  several  months  or  years  of  losses  and  the  cost  of  a  launch
campaign. 
In addition, there are high barriers to entry, as the government, citizens and
support stakeholders have to be involved in a designing process, which is complex
task. To be noted, existing Wizz Air is a mature and stable market; hence, the entry
of new entrants is unlikely to occur.   
First of all, there is a legislation and government action barrier as they both
prefer to develop already existing airline. Such barriers can take the form of tariffs
or regulation of markets. Moreover, the Wizz Air has important opportunities of
economies of scale, making it expensive for new entrants to try and reach such
levels of service that would require both money and time due to the effects of the
experience curve. 
Threat of substitutes
This threat is rather medium with other transportation alternatives not having
the same speed, convenience and flexibility as air travel. If we compare the price/
performance ratio  between a  civil  aircraft  and a  train,  it  is  so  that  the  train is
cheaper even if it has a lower speed performance. Therefore, other transportation
modes and other substitutes remain interconnected and complementary.
Bargaining power of suppliers
Suppliers  provide the airlines with services and goods which relate  to  the
attractiveness to target market. Airlines can outsource service providers basing on
their financial activity, which will directly influence on the price and quality of
service. 
The  services  provided  in  the  airports  by  suppliers  are  mainly:  passenger
search,  hold baggage,  access  control,  trolley circulation,  fire  service,  air  traffic
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control, car park operations, direct retailing, cleaning, passenger handling, baggage
handling,  freight  handling,  fuel  supply.  Therefore,  it  can  be  estimated that  the
suppliers in the airport are vital, but they are price takers. 
Upon completing the analysis of Wizz Air, we can compile them into a chart
that sums up the power of the five forces on five axes. The power diminishes as
points go further on the axes (Figure 2.19).
Fig. 2.19. Comparative industry structure analysis
Rivalry  is  high  for  Wizz  Air,  even  though  the  threat  of  new  entrants  is
relatively low. As said previously, competition is severe on a global scale as more
and more governments aim at  developing ambitious  projects  that  will  generate
high return of  investments.  The threat  of  substitute  is  medium as they provide
primarily interconnected and complementary service.
The supplier power is qualified as low because there is diversified portfolio of
suppliers, which are vital but just a price oriented. 
Regarding  the  entry  threat,  due  to  the  investment  and  time,  the  expected
retaliation barriers together with the legislation action are so important that they
dissuade  new  entrants. For  instance,  strong  relations  between  strengths  and
opportunities  can  suggest  good conditions  in  the  company and allow using an
aggressive strategy. 
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2.6. Conclusions to Analytical part
During analitycal part was selected Wizz Air airline cause during analysis
was shown, very stable in the air carrier market. I also have a good fleet of the
latest aircraft, including for the transport of dangerous goods such as medicines.
He also has a colossal  and successful  experience in the transportation of  ADR
cargo. Everything is performed to the highest IATA standards.
And it is a stable airline that, during the COVID-19 pandemic, managed to
maintain its leadership position in the air carrier market. And also without reducing
the working staff, which numbers thousands of people.
A  distinctive  feature  is functioning  of  new  logistics  technologies  for  the
delivery in long-distance communication is the formation of permanent operational
and organizational and permanent information, management "chain" structures.
The introduction of logistics technologies is also associated with the need to
improve and enhance the efficiency of management and organizational functions
of the physical flow processes of movement of goods and information. 
It  was  found  that  among  the  most  important  factors  for  special  cargo
companies  are:  cost  minimization,  maximizing  supply  efficiency,  complexity
management,  maximizing  supply  flexibility  and  minimizing  risks.  Emphasis  is
placed on the nonlinearity of the links between these factors and the solution of the
multicriteria problem by the participants of the logistics supply chain, which, in
particular, makes it difficult to develop the relevant developments.
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3.1. How much vaccine is needed
The emergence of a vaccine that protects against infection with the SARS-
CoV-2 coronavirus is expected in Ukraine with no less impatience than in other
countries. Therefore, immediately after the news that BioNTech and Pfizer were
going to apply for admission of the vaccine for use and begin its production, the
country  started  talking about  the  possibility  of  purchasing  the  vaccine  and  the
required number of doses.
A preliminary plan for the procurement of the drug has already been drawn
up, told DW in the Ukrainian Ministry of Health. Ukraine also expects that in a
few weeks the research results will be presented by a number of other companies
working on the development of a vaccine against SARS-CoV-2. At the same time,
the Russian vaccine against coronavirus in Ukraine will not be purchased.
"There  is  no  evidence  that  the  vaccine,  which  is  being  discussed  in  the
Russian Federation, has passed all  phases of clinical  trials,  especially the third.
There  are  many  other  vaccine  manufacturers  in  the  world  -  quite  powerful
companies that are at the final stage of clinical trials," said the Minister of Health
of Ukraine Maxim Stepanov.
Ukraine  expects  to  gain  access  to  the  future  vaccine  against  coronavirus
within the framework of the global COVAX initiative, a mechanism designed to
provide countries of the world with equal access to safe and effective vaccines
after their licensing and registration. This initiative is jointly coordinated by the
Coalition for Epidemic Preparedness Innovation (CEPI), the Global Alliance for
Vaccines and Immunization (GAVI) and the World Health Organization (WHO).
COVAX's  mission  is  to  distribute  safe  and  effective  vaccines  among  the
participating countries by the end of 2021 in proportion to their population.
To date, 172 states have joined the COVAX initiative, including Ukraine. The
government  expects  that  for  the  first  stage  of  vaccination  against  COVID-19
COVAX will  provide Kiev with the number of  doses required to vaccinate  20
percent  of  the  population,  says  Serhiy  Litovka,  head  of  the  expert  group  on
immunization of the Ministry of Health of Ukraine
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The Ministry of Health plans to vaccinate the entire population of the country.
For this, Ukraine needs 42 million doses of vaccines if the vaccine is a single one,
or 84 million if a second injection is needed. Under the COVAX program, we are
guaranteed to receive the first eight million doses of the future vaccine
The projected cost of one dose of the vaccine will range from $ 30 to $ 50,
says the head of the expert group on immunization at the Ukrainian Ministry of
Health. According to him, it is planned that countries with a high level of income
will receive the vaccine at the full price, countries with low and middle income - at
a fivefold reduction, and poor countries - for free. Ukraine expects to buy the first
batch of vaccine at $ 8-10 per dose, and part of the doses will be received free of
charge.
Who in Ukraine will be the first to receive vaccinations against coronavirus?
Who  to  get  vaccinated  in  the  first  place,  when  the  coronavirus  vaccine
appears, has already been decided in Ukraine. The Ministry of Health says that the
first in line for vaccination will be people at risk, or those who are in closer contact
with people than other population groups. Priority groups include medical workers,
military personnel and representatives of law enforcement agencies, including the
police, the State Border Service or the National Guard, as well as teachers and
people over 65.
The Ministry of Health has already calculated that for the vaccination of all
priority groups, Ukraine will need 16 million doses of the vaccine - or 32 million
in the case of a double vaccination. And if Ukraine receives eight million doses -
half  of  this  number - within the framework of  the COVAX initiative,  then the
country will  have to  buy the  other  half  at  the full  price,  says  Sergey Litovka.
According to him, both legally and financially,  Ukraine is ready to purchase a
future vaccine produced by any company - provided that the safety of the drug is
proven,  it  will  pass  all  stages  of  testing  with  international  confirmation  of  its
effectiveness and will be officially registered on the international market.
Ukraine is  ready to make purchases,  distribute  the vaccine to  regions and
districts  and  vaccinate.  We  have  capacities  for  storing  vaccines,  there  is  a
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regulatory framework that allows the use of the drug for epidemic indications. But
it all depends on the vaccine manufacturer and on how many doses of the vaccine
it is ready to sell to Ukraine.
The government of Ukraine has put in the draft budget for 2021 more than 2.6
billion hryvnia for vaccination against coronavirus. Whether this money will be
enough to vaccinate 42 million inhabitants of Ukraine is not yet clear. In addition,
not  all  Ukrainians  want  to  be  vaccinated  against  COVID-19:  the  results  of  a
September  study  by  the  Research  &  Branding  Group  sociological  company
showed  that  half  of  the  country's  residents  would  not  even  agree  to  free
vaccination.
Сonditions for storing vaccines in Ukraine.
In  addition  to  the  availability  of  funds  for  the  purchase  of  the  drug from
COVID-19 and the willingness of the manufacturer to provide the required number
of  doses,  another  important  issue  is  the  creation  of  infrastructure  for  the
transportation and storage of the vaccine. So, as far as is known today, vaccines
using synthetic mRNA to activate the immune system - namely, such a vaccine
developed by Pfizer and BioNTech - must be transported and stored at extremely
low temperatures: down to -80 ° C.
The creation of these conditions can be problematic for Ukraine. The head of
the  expert  group  of  the  Ministry  of  Health  on  immunization  says  that  the
infrastructure  for  maintaining  the  "cold  chain"  when  storing  vaccines  in  the
country is there, but it is designed for drugs that are stored at higher temperatures -
from + 2 ° C to + 8 °  C. "The company" Ukrvaktsina "says that  it  is  able to
simultaneously receive, store and logistically distribute 30 million doses of vaccine
at temperatures from + 2 ° C to -20 ° C. If it is lower, for example, -80 ° C, then we
also have refrigeration equipment - but to a lesser extent, "Sergei Litovka noted.
Ukrainian Health Minister Maxim Stepanov said that Ukraine will not buy the
Russian vaccine, since it has not passed the third stage of clinical trials.
There is no evidence in the world that the vaccine that they are talking about
in the Russian Federation has passed all phases, especially the third, clinical trials.
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The third stage involves a large number of people who are volunteers. Now there is
not even a subject of conversation for discussion - to buy or not.
The minister noted that, first of all, one must understand the safety of any
vaccine and only then can it be recommended. He added that any vaccine must
pass certain stages of clinical trials before being registered.
As for free tranches of the vaccine, they can be expected in the first half of
2021.The Minister of Health Maxim Stepanov told about it during a briefing on
November 20. "By December 7, we must sign all technical documents. We expect
that in the first half of 2021 we will begin to receive appropriate vaccines. The first
tranche is 1.2 million doses, "Stepanov said. As mentioned earlier, priority groups
that are at risk will be vaccinated as a matter of priority.
The country is ready to accept even ultra-cold vaccines. Ukraine is ready, in
particular, we have refrigeration units that are able to store the vaccine even at
temperatures up to -70 ° C, if any.
COVAX,  the  vaccines  pillar  of  the  Access  to  COVID-19  Tools  (ACT)
Accelerator,  is  co-led  by  the  Coalition  for  Epidemic  Preparedness  Innovations
(CEPI), Gavi, the Vaccine Alliance, and the World Health Organization (WHO) –
working  in  partnership  with  developed  and  developing  country  vaccine
manufacturers. It is the only global initiative that is working with governments and
manufacturers  to  ensure  COVID-19  vaccines  are  available  worldwide  to  both
higher-income and lower-income countries.
In order to be able to secure enough doses of vaccines to protect the most
vulnerable populations, such as health workers and the elderly, the next step for the
partnership is to confirm potential self-financing participants’ intent to participate
by 31 August and to turn these into binding commitments to join the COVID-19
Vaccine Global  Access Facility (COVAX Facility) by 18 September, with first
upfront payments to follow thereafter, and no later than 9 October 2020.
“Equal access to a COVID-19 vaccine is the key to beating the virus and
paving  the  way  for  recovery  from  the  pandemic,”  said  Stefan  Löfven,  Prime
Minister of Sweden. “This cannot be a race with a few winners, and the COVAX
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Facility is an important part of the solution – making sure all countries can benefit
from access to the world’s largest portfolio of candidates and fair and equitable
distribution of vaccine doses.”
The COVAX Facility is a Gavi-coordinated pooled procurement mechanism
for  new  COVID-19  vaccines,  through  which  COVAX  will  ensure  fair  and
equitable access to vaccines for each participating economy, using an allocation
framework currently being formulated by WHO.T
he COVAX Facility will do this by pooling buying power from participating
economies and providing volume guarantees across a range of promising vaccine
candidates, allowing those vaccine manufacturers whose expertise is essential to
large scale production of the new vaccines, to make early, at-risk investments in
manufacturing capacity – providing participating countries and economies with the
best chance at rapid access to doses of a successful COVID-19 vaccine.
The goal of COVAX is by the end of 2021 to deliver two billion doses of
safe,  effective  vaccines  that  have  passed  regulatory  approval  and/or  WHO
prequalification.
These  vaccines  will  be  offered  equally  to  all  participating  countries,
proportional  to  their  populations,  initially  prioritising  healthcare  workers  then
expanding to  cover  vulnerable  groups,  such as  the elderly and those with pre-
existing conditions.
Further  doses  will  then  be  made  available  based  on  country  need,
vulnerability  and COVID-19 threat.  The COVAX Facility  will  also maintain a
buffer of doses for emergency and humanitarian use, including dealing with severe
outbreaks before they spiral out of control.
To date, a total of 184 countries participate in the COVAX Facility, being 92
of them low and middle-income economies eligible to get access to COVID-19
vaccines through Gavi COVAX Advance Market Commitment (AMC).
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3.2. Amount of money that country needs to buy vaccine
According to V. Lyashko, the commercial proposal was sent by a company
from China, which is the first in the WHO list of developers.
“The vaccine will cost around $ 20, that is, about UAH 500 per dose. It will
be necessary to vaccinate twice, ”said the chief sanitary doctor and specified that to
protect a person from COVID-19, about 1000 hryvnia will be needed.
According to him, the timing of when it will be possible to buy the vaccine is
not  known,  because  clinical  trials  are  still  being  conducted,  there  are  no
instructions, the drug has not been registered.
In  terms  of  vaccination  of  the  population,  it  is  planned  to  cover  40% of
citizens for the funds of the state budget. First of all, they will vaccinate medical
workers and law enforcement officers.
“The second stage is the elderly, since this is the largest risk group. We have
6-7 million of them today. In the future - people with chronic diseases, ”added V.
Lyashko. How much money will have to be allocated for this, the representative of
the Ministry of Health promised to announce later.
The minister explained that people who have had coronavirus may have a
decrease in the number of  antibodies over time. Accordingly,  such a person is
again at risk of infection.
"The vaccine produces antibodies that fight the virus. If a person who has
relapsed begins to lose antibodies, it is clear that they need to be updated, it is also
at risk, especially if it is at risk. But you will need to look at a specific vaccine. ", -
Stepanov explained.
The head of the Ministry of Health also expressed hope that the coronavirus
vaccine would be delivered to Ukraine at the international initiative of COVAX
next year, 2021. Currently, the Ministry conducts daily negotiations for the vaccine
with various companies.
"By December 7, we have to sign all the technical documents with them all to
get the vaccine under this mechanism, it's 8 million doses. In addition, there are
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talks with other companies, they go every day. I hold meetings every day, and
there is a corresponding dynamics with others. companies in which we intend to
buy the vaccine.
The second issue concerns the trust in vaccination in Ukraine. We have a flu
vaccine, but in Ukraine only half a percent of the population is vaccinated against
the flu. And against  the background of mistrust, the emergence of even such a
dissident movement against the coronavirus, when people do not believe in the
presence of the virus itself, this may be another deterrent to the average Ukrainian
about  the  availability  of  these  vaccines.  Because  it  is  very  difficult  for  us  to
convince manufacturers that we will buy this vaccine or the private market will
buy this vaccine.
And the third is the issue of safety and effectiveness, which is currently being
discussed,  with  people  following  various  reports,  such  as  side  effects  or
inefficiencies. Given that two doses will need to be given, this will also affect the
availability of this vaccine. If we talk about masculinity and real accessibility, I
think it can take three to five years.
It is pharmaceutical products that are the leader in imports to Ukraine. The
fastest and most reliable way to deliver pharmaceuticals is by air. In addition to the
production process and the actions of medical personnel, the quality of imported
drugs  also  depends  on  how  much  the  carrier  company  and  the  logistician
controlling the entire process will understand the nuances of such transportation,
because the transportation of pharmaceutical products requires the use of special
equipment and the availability of specialized knowledge and skills.
Such transportation takes from a week to two. It is easy to guess that during
this  time  the  cargo  goes  through  various  stages  of  registration  and  direct
transportation, and the slightest mistake can affect the quality and suitability of the
drug.
The main indicators that require careful monitoring during transportation are
temperature, humidity and lighting. In particular, vaccines require compliance with
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a certain temperature regime, the violation of  which leads to a change in their
pharmacological properties.
Temperature requirements are specified by the manufacturer.  For example,
for many vaccines, the optimal temperature is from +2 to +8 ° C. But the vaccine
for  the  prevention  of  poliomyelitis  is  recommended  to  be  stored  frozen  at  a
temperature from -15 to -25 ° C. When storing and transporting the vaccine at a
temperature of +2 to +8 degrees ... The shelf life of such a vaccine is six months.
Vaccines  should  be  transported  by  refrigerated  transport  in  thermal
containers,  with indicator  cards,  freezing indicators  and thermotesters.  Thermal
indicators are considered cheap, but not very reliable means of control. 
These  are  disposable  color  film  indicators  that  show  only  the  fact  of  a
violation of the temperature regime, but do not say anything about the duration of
this  violation.  If  the  cargo  is  transported  in  several  stages,  it  is  better  to  use
thermostats.
Loading of drugs into thermal containers is carried out in the refrigerating
chamber. In some cases, loading at room temperature is allowed, but not more than
10 minutes.
Bulk storage warehouses should have enough thermal containers, ice packs,
indicator cards, freeze indicators, thermotesters and thermostats. The warehouses
must adhere to the appropriate air humidity and lighting regime (Light should not
fall on vaccines).
It is prohibited to store vaccines together with other medicines and foreign
objects,  as  well  as  storage in refrigerator  doors.  A contingency plan should be
developed at each stage of transportation.
The carrier company must have a sufficient number of refrigerated vehicles to
ensure transportation in full compliance with the cold chain, including taking into
account force majeure situations.
The  vehicle  must  be  equipped  with  a  driver  alert  system  in  case  of
temperature changes.
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In order to check the condition of the cargo during the entire transportation,
wireless sensors are used in air transportation, which are in "sleep" mode during
the flight and record data. This active wireless sensor sends information about the
temperature of the cargo (and about humidity in the future) in real time to the
receiver, so called wireless sensor gateways (USG), which forward the data via
LAN or GPRS to the monitoring tools of the logistics service provider. Thus, you
can track the cargo in real time and see if the temperature meets the established
standards.
After air transportation, it is important to check once again the observance of
temperature  standards,  as  well  as  the  integrity  of  the  package.  The  product  in
damaged packaging cannot be sold. In addition to health hazards, these are also
reputational risks for the manufacturer.
It is important to avoid shipment of an expired vaccine, or vaccine that is less
than  one  month  old.  The  responsible  person  should  have  an  agreed  delivery
schedule for vaccines and monitor the expiration dates of the drugs.
Further  -  the  process  of  safe  storage  of  drugs  in  pharmacies,  healthcare
institutions and the possible last stage of transportation.
It is important to know that the transport of vaccines by courier services is
prohibited. The buyer can personally deliver the vaccine to the vaccination room,
having previously taken care of the availability of a thermal container. Or use the
corresponding  service  of  the  network  of  pharmacies.  At  the  same  time,  it  is
important to check the integrity of the packaging, the presence of documents and
the indicators of the temperature indicator.
Delivery of pharmaceutical products,  including vaccines,  is a very delicate
process. Any mistake during the transportation stage can lead to financial losses,
reputational risks and have a negative impact on the health of patients. That is why
all participants in this process should be aware of their responsibility not only to
business, but above all to humanity.
Packaging  system for  the  packing  and  labelling  of  Category  B infectious
substances  is  UN3373 described in  theoretical  part  of  this  work.  It  includes  5
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positions for transporting tubes. As a relust, we can transport 5 points of vaccine in
one package.
According to the information that is united in the media, the first purchase of
the vaccine will be for 8 million units of injections. Now we need to calculate how
many of these boxes will fit into the cargo plane of the airline we have chosen.
As  a  new-generation  freighter  derived  from Airbus'  proven  A330  jetliner
family,  the  A330-200F  offers  highly-efficient  operation  with  less  noise  and
emissions than mid-sized cargo aircraft in service today. Customers have praised
the A330-200F for  its  outstanding flexibility, which is further  enhanced by the
freighter’s full operational commonality with Airbus’ fly-by-wire family of single-
aisle and wide-body jetliners. In addition, its large main deck cargo door allows the
aircraft to accept all commonly-used pallets and containers.
The  A330-200F  is  a  medium-sized  long-haul  cargo  aircraft  capable  of
carrying cargo weighing 65 tons over a distance of 4,000 nautical miles (7,400 km)
or 70 tons of cargo over a distance of up to 3,200 nautical miles (5,950 km). The
aircraft uses a new universal loading system on the upper deck, which allows you
to place both pallets and containers. There are several options for arranging cargo
on the upper deck, designed for different markets and cargo flows.
To compensate for the nose roll of the A330 in the ground position, the front
rack of  the chassis  has  been redesigned.  The standard  rack A330-200 is  used,
however  the  top  point  of  its  fastening  is  shifted  downwards  that  required
installation in the lower forward part of a fuselage of the blister covering a rack in
the removed position.
This solution made it possible to obtain a flat surface of the upper deck. The
powerplant consists of two Pratt & Whitney PW4000 or Rolls-Royce Trent 700
engines.  General  Electric  does  not  plan  to  offer  engines  for  the  A330-200F
modification.
In addition to the production of new aircraft, Airbus has offered a program to
convert passenger A330-200 into cargo.
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Fig 3.1 Airbus A330 specifications
Fig 3.2 Airbus A330-200F view
he  A330-200F  features  a  common  flight  deck  with  the  A330  passenger
variant and virtually identical flying qualities with the A320, A340, A350XWB
and A380 Families. Today airlines are benefitting from significant savings through
reduced training requirements and a common pool of pilots. For a pilot already
qualified on the  passenger  variant,  only  computer-based training is  required in
transitioning to the all-cargo version.
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Airbus  is  a  leading  aircraft  manufacturer  with  the  most  modern  and
comprehensive family of airliners on the market. Based on the highly successful
A330-200, the A330-200F is the only new mid-sized,  long-haul freighter.  This
flexible  and  technologically  advanced  aircraft  builds  on  Airbus’  successful
experience in the regional freighter market and benefits from the experience of
over 1,000 in-service A330s.
The  A330-200F  has  payload,  range  and  economics  superior  to  previous
generation freighters, carrying 70 tonnes with a range up to 4,000nm / 7,400km.
As the most efficient, profitable and reliable freighter of its generation, the A330-
200F provides similar unit costs compared to larger freighters.
Its  versatile  main  deck  accommodates  standard  industry  pallets  and
containers, but also enables to carry oversized cargo with 16ft/20ft pallets. With
the A330-200F you can be sure that your temperature or time sensitive goods are
transported  in  optimal  conditions.  It  will  support  you every day to  deliver  the
highest quality of services to your customers.
In today’s market  larger freighters  struggle to  gather sufficient  payload to
reach profitability, resulting in more risk and lower frequencies. The A330-200F
was  launched  to  answer  the  need  for  efficient,  mid-size  aircraft  that  could  be
operated  on thinner  or  frequency driven markets  with economics  equivalent  to
those of larger freighters. For example, at 70 tonnes, the A330-200F cost per tonne
is 35 % lower than that of a larger freighter. Fuel-efficient technologies, flexible
cargo configurations  and optimised load factors  make the A330-200F a  highly
cost-efficient freighter.
Fig 3.3 Precess of Airbus A330-200F loading
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Looking on scheme of  cargo loading we can’t  count  how much UN3373
packages can be loaded in one Airbus A330-200F.
Fig 3.4 Airbus A330-200F scheme of cargo loading
The term "general packaging" is used in cases where several packages are
combined into one cargo and sent to the same destination by one consignor. If for a
refrigerant is used to protect the contents; be isolated vessels or flasks. If general
packaging is used, the outer surface must also have all the necessary stickers and
labels that available on separate packages. This requirement applies to infectious
Category A and B materials.  In addition, the general  packaging must read
“general packaging". Coolants  can  be  used  to  stabilize  infectious materials  of
category A and B during transportation.
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Ice or dry ice should be placed outside the secondary packaging. Plain ice is
placed in a sealed waterproof container; the outer packaging must also be sealed.
Dry ice should not be placed inside the primary container or secondary packaging
due  to  the  risk  of  explosion.  When transporting  goods  with  dry  ice,  a special
separate packaging. If dry ice is used, the packaging should provide free exit of
evaporated carbon dioxide. Follow the instructions 904 ICAO / IATA.
Secondary packaging must be reinforced in the outer packaging in such a way
that ensure that the correct position of the inner packagings is maintained after the
coolant will dissolve or evaporate. If dry ice is used for the carriage of infectious
substances in Category A, In the Dangerous Goods Declaration, the shipper must
provide details. Besides in addition, there must be a sticker on the outside of the
outer packaging, indicating the use of dry ice (see fig. 4), and the corresponding
markings. If a dry ice is used for the transport of infectious substances of category
B, on packaging should indicate "Carbon dioxide, solid" or "Dry ice";  in these
guidelines this issue is not considered in more detail.
If  liquid nitrogen is used as a coolant,  it  is  necessary to provide a special
arrangement  with  the  carrier.  The  primary  container  must withstand  ultra-low
temperatures, and packaging and documentation must comply requirements for the
use of liquid nitrogen. 
In particular, on the outside the surface of the outer packaging must have an
appropriate sticker to indicate use of liquid nitrogen. 
When transported by air packaging must also have a sticker indicating the use
of cryogenic liquids in these recommendations, this question is not in more detail
is being considered. 
The  principle  of  triple  packing  continues  to  operate,  including  for  local
shipments by land transport. However, packaging test results documents are not
required. Instead of looking for a reputable supplier,  you can use local sources
packaging materials, provided that both the container manufacturer and the sender
fully comply with the requirements of document P650.
110
Fig 3.5 Example of a completed "Shipper's Declaration for Dangerous Goods"
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For instance, in aviation the most important resource is a current fleet. Basing
on previous investigation and analysis of a current market state, it should be done
aircraft evaluation and fleet planning. The choice of an aircraft, as well as overall
operating  fleet  is  the  important  long-term strategic  decision  of  an  airline.  The
actual fleet of an airline is commonly planned on the basis of current situation on
the  market,  transport  demand  and  facilities,  which  further  would  provide
maintenance of aircraft (emphasize on expenses). 
All these factors have an influence on the transport mean choice, but their
impact varies moderately (Figure 3.6).
Fig.3.6 Main factors, which influence the choice of an aircraft
Firstly, the airline considers which kind of flights would be served by the
aircraft, depending mostly on the demand. Commonly, if the demand of already
existing routes increasing - the usage of larger aircraft is more sufficient, while
there is a necessity  to open a new route  - the choice of an aircraft is based on the
needed fling capacity and range. 
In case of an increasing of a demand:
 Higher service frequency (reducing passenger and cargo delay);
 Higher aircraft size (increasing productivity in terms of passenger and
cargo transported; range of flight increases).
Secondly,  the  airport  characteristics  are  important.  When  introducing  new
aircraft should be taken into account terminal capacity of an airport, which would
be a part of transportation process. This could include availability of maintenance
of transport vehicle, acceptable areas and technologies for processing cargo and
passenger as well as readiness to serve more flights (case of increasing service
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frequency). The status of an airport if it is hub or a spoke must be considered,
while the usage of regional jets during fly from spoke to a hub is more rational
(availability  to  benefit  with  comparatively  less  expenses  with  providing  more
frequent flies to a hub.)  The flights from the hub are carried out by the larger
aircrafts.
Large  aircraft  are  more  expensive  to  serve  in  the  airport,  which can also
influence on the choice of aircraft:
 The charges are calculated on the basis of the weight of aircraft;
 Personnel has higher salaries;
 Runway capacity price.
Thirdly, environmentally friendly airlines as well as governmental authorities
consider the environmental issue is one, which affects the decision making.
Long  haul  routes  were  excluded,  while  the  frequency  of  operation  is
considerably lower than on short haul routes and the airlines already prefer to use
large aircrafts, which is more efficient. At the same time the flight with that ranges
can be performed by large aircrafts only. While there is a flight from hub, usually
the commercial load is higher as well which provoke necessity in higher maximum
payload. 
To predict the operational and financial efficiency of new airline creation, it
should be done market share and revenue forecasting. It is hard to do, because as it
was  stated  before,  aviation  is  too  global  business,  which  depends  on  world’s
market state which is hard to anticipate.
3.3 Development of optimal vaccine delivery schemes
The GAVI Vaccine Alliance is a public-private partnership that helps ensure
that half of the world's population is vaccinated against a range of deadly diseases.
Since  its  founding  in  2000,  the  Alliance  has  helped  immunize  more  than 760
million children, a generation, and prevented over 13 million deaths, helping to
halve child mortality in 73 developing countries. 
113
The  Alliance  also  plays  a  critical  role  in  strengthening  global  health  and
safety  by  supporting  health  systems  and  funding  global  stockpiles  of  Ebola,
cholera, meningitis and yellow fever vaccines. The GAVI Alliance is now building
on 20 years of successful experience to protect a new generation and reach out to
unvaccinated people whose needs were previously neglected, using state-of-the-art
technology -  from drones  to  biometric  systems -  to  save  millions.  other  lives,
timely containment of outbreaks of epidemic potential, and help countries achieve
self-reliance.
The Vaccine Alliance brings together developing and donor governments, the
World Health  Organization,  UNICEF,  the World Bank,  vaccine  manufacturers,
technical  agencies,  civil  society  organizations,  the  Bill  &  Melinda  Gates
Foundation and other private sector partners.
In July, the GAVI Board agreed on a list of 92 countries that will receive
COVAX support under Preliminary Purchase Commitments (PRPs). Below is a
complete list of these countries.
Low-income countries: Afghanistan, Benin, Burkina Faso, Burundi, Central
African  Republic,  Chad,  Democratic  Republic  of  Congo,  Eritrea,  Ethiopia,
Gambia,  Guinea, Guinea-Bissau,  Haiti,  Democratic People's  Republic of Korea,
Liberia, Madagascar, Malawi , Mali, Mozambique, Nepal, Niger, Rwanda, Sierra
Leone, Somalia, South Sudan, Syrian Arab Republic, Tajikistan, Togo, Uganda,
United Republic of Tanzania and Yemen.
Lower  middle  income  countries:  Angola,  Algeria,  Bangladesh,  Bhutan,
Bolivia,  Cape  Verde,  Cambodia,  Cameroon,  Comoros,  Congo,  Ivory  Coast,
Djibouti, Egypt, El Salvador, Eswatini, Ghana, Honduras, India, Indonesia, Kenya,
Kiribati,  Kyrgyzstan,  Lao  People's  Democratic  Republic,  Lesotho,  Mauritania,
Micronesia,  Moldova,  Mongolia,  Morocco,  Myanmar,  Nicaragua,  Nigeria,
Pakistan,  Papua  New  Guinea,  Philippines,  Sao  Tome  and  Principe,  Senegal,
Solomon Islands, Sri Lanka, Sudan, Timor-Leste, Tunisia, Ukraine, Uzbekistan,
Vanuatu, Vietnam, West Bank and Gaza, Zambia and Zimbabwe.
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Other  countries  eligible  for  assistance  from the International  Development
Association (IDA): Dominica, Fiji, Grenada, Guyana, Kosovo, Maldives, Marshall
Islands, Samoa, Saint Lucia, Saint Vincent and the Grenadines, Tonga and Tuvalu.
Of the nine candidate vaccines currently being evaluated for inclusion in the
COVAX mechanism, two are being developed in China, two in the United States
of America, one in the Republic of Korea, one in the United Kingdom of Great
Britain  and  Northern  Ireland,  and  one  more  globally.  partnerships  of  various
manufacturers.
According to the data on the COVAX website, most likely the vaccine will be
supplied to European countries from United Kingdom of Great Britain, the United
States will take the left hemisphere of our planet under its wing, and China will
cover  the  countries  of  Asia.  So,  to  calculate  the  route  for  the  delivery  of  the
vaccine to Ukraine, The United Kingdom of Britain was chosen.
Fig 3.7 Distance from London to Kiev
The  flight  distance  between  the  nearest  airports  London,  England,  GBR
(LCY) and Kiev, UKR (IEV) is 1,316.09 mi (2,118.04 km). This corresponds to an
approximate flight time of 2h 59min.
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The geographic midpoint between London, England, GBR and Kiev, UKR is
in 662.93 mi (1,066.88 km) distance between both points in a bearing of 81.03°. It
is  located  in  Polska,  Lubusz  Voivodeship,  powiat  zielonogórski,  gmina
Czerwieńsk  (Polska,  województwo  lubuskie,  powiat  zielonogórski,  gmina
Czerwieńsk).
The time difference between London, England, GBR (Europe/London) and
Kiev, UKR (Europe/Kiev) is 2 hours. This means that it is now 14:07 (02.12.2020)
in London, England, GBR and 16:07 (02.12.2020) in Kiev, UKR.
Fig 3.8 Distance from London to Kiev
To carry out its activities, the airline needs a slot.
Slot - a place in the schedule, the schedule of takeoffs and landings at the
airports of departure and arrival.
Regulatory documents that establish the principles of slot allocation are the
recommendations of ICAO "Regulatory aspects of the allocation of" windows "for
the arrival and departure of flights at international airports and IATA "Worldwide
Scheduling Guidelines".
Ukraine has rules for granting permits to operators to depart from Ukrainian
airports and arrive at Ukrainian airports during international, domestic and transit
flights.
One of the most important concepts of the IATA slot allocation system is the
historical precedent for a particular slot, which the airline used effectively (at least
80%) in the same season last year. The right to a slot is in fact reserved for airlines,
although legally these rights are not indicated in any way.
The second main point  is  the  right  of  airlines  to  exchange received slots.
Outwardly, it looks like a simple exchange, however, the airline buyer not only
116
gives  the  seller  an  unnecessary  or  little  used  slot,  but  often  receives  a  certain
amount for it.
The IATA slot allocation system has been operating for 66 years. However,
we should not forget that in parallel with the official mechanisms of the airline use
the opportunities of the "gray market".
The aircraft  schedule is  the main program document of  the airline,  which
regulates the activities of all its services. The basis for scheduling is the plan of the
aircraft.
When drawing up the flight schedule, it is necessary to take into account the
flight and working hours of the crew - the sanitary norm. According to the Rules
for  determining  the  working  time  and  rest  time  of  crews  of  civil  aircraft  of
Ukraine, the duration of daily work of aircraft crew members should not exceed 12
hours with subsequent rest time.
Route under consideration:
London Heathrow Airport (LHR) – Kyiv Zhuliani (IEV) - London Heathrow
Airport (LHR)
Estimated flight time is 3 hours.
We depart from London Heathrow Airport (LHR) at 08:30, arrive in Kyiv
Zhuliani (IEV) (08:30 + 3:00) at 13:30. The time difference between Ukraine and
Great Britain is - 2 hours in summer and + 2 hours in winter.
Then we depart from IEV airport at 10:00 am, arrive in LHR (08:30 + 3:00) at
9:30 pm local time in London.
Table 3.1
Schedule of  connecting flights
Flight Airport  of
departure
Destination
airport
The  day  of
the  week
when  the
flight  is
performed
Departure
time
(behind
Kyiv)
Arrival time
(local  time
in London)
AD 714 Heatrow
(LHR)
Zhuliani
(IEV)
Thursday 08:30 13:30
AD 713 Zhuliani
(IEV)
Heatrow
(LHR)
Monday 08:30 09:30
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Calculate the cost of the flight Kiev - London.
All planned costs for the flight  Еflight consist  of direct  Еdir and indirect  Еind
costs.
Еflight = Еdir + Еind (3.1)
Direct costs are calculated by the formula:,
Еdir = Еfc + Еrest + Еrepc + Еlabc + Еdsot + Еinsu + Еflcost + Еnavfee + Еafee (3.2)
where Еfc – fuel costs, UAH / flight;
Еrest – costs for full restoration of the aircraft, UAH / flight;
Еrepc - maintenance and repair costs, UAH / flight;
Еlabc – labor costs of aircraft crew members, UAH / flight;
Еdsot – deductions for social and other obligatory types of insurance, UAH /
flight;
Еinsu - aircraft insurance costs, UAH / flight;
Еflcost – other flight costs, UAH / flight;
Еnavfee – air navigation fees, UAH / flight;
Еafee - airport fees, UAH / flight.
Based on the flight speed on the flight (its section), the planned level of flight
duration on a single flight (in one direction) and on each non-stop section of the
flight is determined:
,
V
L
t
.p
p   (3.3)
where Vр - flight speed, km / h;
L - distance between airports on the flight route, km;
tp = 2150 / 750 = 2,9 hour
The execution time of a single or even flight is determined by the sum of the
flight time on all sections of the flight. In the planned calculations, the time of the
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entire flight  and the time of flight  on all  sections  is increased due to the non-
production raid associated with the implementation of training and auxiliary flights
on the aircraft.
Thus,  the planned cost  of  aviation fuel  on the flight  is  determined by the
formula:
Efc = (1+ Кnon-ph)g × СCTF × tр, (3.4)
where Кnon-ph -  coefficient  that  takes  into  account  the  non-productive  raid
hours;
g – fuel consumption on average per hour, t;
СCTF  - the cost of one ton of aviation fuel at airports;
tр – flight duration, h.
According to formula 3.4, the planned costs for aviation fuel on the flight will
be:
Efc = (1+ 0.05)4 × 1000 × 2,9 = 12,180$/hour
Calculate  the  amount  of  depreciation  for  the  restoration  of  assets,  which
include  all  spare  engines,  as  well  as  those  under  repair.  Depreciation  of  fixed
assets, according to the "Accounting Regulation 7" Fixed assets ", approved by the
Order of the Ministry of Finance of Ukraine 27.04.2000 №92" is calculated using
the following methods:
1. rectilinear;
2. reduction of credit value;
3. accelerated reduction of residual value;
4. cumulative;
5. production.
The state regulates the remuneration of employees of enterprises of all forms
of ownership by setting the minimum wage and other state norms and guarantees,
establishing  the  conditions  and  amounts  of  remuneration  of  managers  of
enterprises  based  on  state,  communal  property,  employees  of  enterprises,
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institutions and organizations funded or subsidized. from the budget, regulation of
wage  funds  of  employees  of  monopoly  enterprises  in  accordance  with  the  list
determined  by  the  Cabinet  of  Ministers  of  Ukraine,  as  well  as  by  taxation  of
employees' incomes.
The conditions of remuneration of employees of institutions and organizations
financed  from the  budget  shall  be  determined  by  the  Cabinet  of  Ministers  of
Ukraine, except for the case provided for in part one of Article 10 of this Law "On
Remuneration of Labor".
Flight costs of flight crews are determined on the basis of the selected system
of remuneration - hourly. For the commander of the aircraft the salary is $ 80, for
other crew members - $ 60, for flight attendants - $ 20. per hour of flight. Total on
board: 1 commander, 1 co-pilot, 1 flight engineer and 2 flight attendants.
Calculated by the formula:
Еlabc = (80 + 2 × 60 + 2 × 20) × 2,9 = 700$,  (3.5)
Expenditures  on  social  and other  types  of  compulsory  insurance  of  flight
crews include insurance contributions for social needs to the Pension Fund, the
Social  Insurance  Fund,  the  Compulsory  Health  Insurance  Fund,  and  the
Employment Fund.
In 2018, the insurance premiums transferred by the insured persons referred to
in paragraphs 1, 2 and 5 of Article 14 of the Law of Ukraine “On Compulsory
State Pension Insurance” to the solidarity system are paid in the amount of 33.2
percent. In this case, the insured referred to in paragraphs 1 and 2 of Article 14 of
the Law of Ukraine "On Compulsory State Pension Insurance" for employees from
among the flight crews of civil aircraft and flight operators who perform special
work  in  flight  pay  insurance  premiums  in  the  amount  of  42  interest  and  for
working disabled people - 4 percent. 
Enterprises of all-Ukrainian public organizations of disabled people, where
the  number  of  disabled  people  is  at  least  50  percent  of  the  total  number  of
employees,  pay  insurance  premiums  at  the  rate  of  4  percent  of  the  object  of
taxation for all employees of these enterprises.
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These costs are determined by the following formula:
Еdsot = Еlabc  × Kded  (3.6)
where: Kded - coefficient of deductions for social needs (take for 0.397).
According to formula 3.6, the costs of social and other types of compulsory
insurance of flight crews will be:
Еdsot = 700 × 0.397 = 278$
Other  flight  costs  associated  with  the  implementation  of  transportation
include the costs of freight forwarding organizations, insurance and intermediary
organizations, agents and air transport agencies, the cost of which is included in
the cost of transportation:
Еflcost = (Сoth. × tр.) / Тper  (3.7)
where: Сoth.  – other airline flight costs for a specific type of aircraft;
tр. – flight duration taking into account all sections of non-stop range, h;
Тper  - production plaque of a specific type of aircraft fleet.
According to formula 3.7, other flight costs will be:
Еflcost = (5500000 × 2,9) / 3500 = 4560$
For  airport  service  of  aircraft  (hereinafter  -  the  aircraft)  and  passengers,
related to the provision of: landing and take-off of the aircraft, passenger service at
the airport, emergency parking of the aircraft, aviation security, airport fees are
charged.
The charge for landing and take-off of the aircraft is set for each ton of the
maximum  take-off  mass  (hereinafter  -  MRM)  of  the  aircraft,  specified  in  the
certificate of suitability for flight, depending on the type of service.
The fee for  publication  in  international  aviation  directories  is  $  10.50 for
international flights. US for 1 ton of MZM PS.
If the landing-take-off of the aircraft at the airport is carried out in accordance
with the purpose of a regular or charter airline, landing on an international flight,
and departure on a domestic or vice versa (with a corresponding change of flight
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number), the landing-take-off fee is set at 50 percent fees according to the types of
connections.
A coefficient of 0.5 is applied to the landing-take-off fee.
The fee  for  passenger  service  at  the  airport  for  publication  in  reservation
systems is $ 17.00 for international services. US for each passenger sent.
Airport fees, which are attributed to a particular flight, are determined on the
basis of the declared fees and the coefficient of their reduction due to government
regulation:
Еafee = k(Еfeetof + Еfeecom + Еfeetground)  (3.8)
where Еfeetof –  the  total  amount  of  fees  for  takeoff  and  landing  and
maintenance of the aircraft at the airports of the airline, UAH;
Еfeecom  – the total amount of fees for commercial service of passengers, mail,
luggage and cargo at airports, UAH;
Еfeetground – the total amount of fees for ground handling of aircraft at airports,
UAH; 
k – the coefficient of reduction of airport charges.
According to formula 3.8, the airport fee will be:
Еafee = 0,5(10,5 × 175,5 + 17 × 130 + 3500) = 3780$
Air navigation charges for the flight consist of service charges on the route
(R) and boarding fee (Еfeetof):
Еnavfee= Еpos + R (3,9)
Тоді постійні витрати будуть складати:
Еpos = 187,5$
The fee for air navigation services of aircraft (AIR) in the airspace of Ukraine,
related to  the organization of  air  traffic  (ATS) on the route,  as  well  as  on the
approach and in the area of the aerodrome, air navigation fees are charged at fixed
rates.
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The rates of air navigation fees are set regardless of the nationality of the
aircraft and the form of ownership of the airline.
The fee (R) for air navigation service of aircraft in the airspace of Ukraine,
related  to  the  provision  of  ATS on the  route,  is  determined depending on the
maximum  permissible  takeoff  mass  of  the  aircraft  specified  in  the  operator's
certificate, orthodromic distance and unit rate.
The unit rate (T) for ATS services on the approach and in the aerodrome area
for international flights is $ 8.55. USA.
Fee for service on the route for 100 km of orthodrome distance is calculated
by the formula:
k
50
G
TDR  ,  (3.10)
where: Т – a single rate of service fee on the route for 100 km of orthodrome
distance;
D – orthodromic distance, km;
G – take-off mass of the aircraft, t;
k – coefficient of reduction of air navigation fees.
According to formula 3.10, the service charge on the route is:
R = 50,96 × 49,3 × (√(175,5/50) × 0,3) = 2578$
Then the air navigation fee will be:
Еnavfee= 187,5 + 2578 = 2765,5$
Insurance protection includes: compulsory insurance of aircraft; compulsory
insurance of the aircraft operator's liability for damage caused to third parties and
the air carrier's liability for damage caused to passengers,  luggage, mail, cargo;
compulsory insurance of aircraft crew members and other aviation personnel.
The minimum insurance  coverage  in  respect  of  liability  to  passengers  for
luggage and cargo should be:
a) in front of the passenger - SDR 250,000 (USD 378,825) for each passenger.
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b) for passenger luggage - SDR 1,000 (USD 1,515.3) for each passenger.
c) for cargo - SDR 17 (USD 25.76) for each kg.
The sum insured established by the compulsory insurance contract must not
be less than the book value of the aircraft.
The costs of aircraft insurance, which are attributed to the flight, require a
preliminary distribution of total costs for all types of aircraft insurance for each
type with the subsequent distribution of the amount received for each flight:
Еinsu = Сinscos  × tр / Тprod  (3.11)
where Сinscos - costs of the airline for the insurance of the fleet of a specific
type, UAH;
tр - flight duration taking into account all sections of non-stop range, h;
Тprod – annual production raid of a specific type of aircraft fleet.
According to formula 3.11, the costs of aircraft insurance will be:
Еinsu = 2000000 × 2,9 / 3500 = 1660$
Therefore, the direct costs are (according to formula 3.2):
Еdir = 12180 + 700 + 278 + 1660 + 4560 + 2765,5 = 22145$
Indirect costs are taken as 40% of direct costs:
Еnepr = 0,4 x Еpr  (3.12)
Еnepr = 0,4 x 22145 = 8858$
The total cost of the flight is:
Еflight = 22145 + 8858 = 31003$
Now we need to calculate how much vaccine an cargo aircraft can carry in
one flight in order to calculate the number of flights that we need to transport the
first batch of vaccine.
The total volume of our aircraft is.
One UN3373 package takes up space.
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The total volume Airbus A330-200F aircraft is:
Sector A (1-16) 223cm x 317cm;
Sector B (17-20) 223cm x 317cm;
Sector B (21-23) 153 x 317cm
Sector B (Y + Z) 17 m²
So now, we need to calculate total m² of our aircraft:
Sector A (1-16) 2.23m x 3.17m x 16 = 113 m² x 0.96 = 110 m³;
Sector B (17-20) 2.23m x 3.17m x 4 = 28 m² x 0.96 = 27 m³;
Sector B (21-23) 1.53m x 3.17m x 3 = 14 m² x 0,66 = 9 m³;
Sector B (Y + Z) 17 m² x 0,66 = 11 m³.
To summarise 110 + 27 + 9 + 11 = 157 m³.
Our package UN3373 is 30x30x30cm. It is 0.027m³
To calculate one full loading of amount of packages UN3373, we need:
157 m³ / 0,027 m³ = 5800 units.
One our UN3373 package can contain 30 positions for vaccine:
It means, that during one flight our Airbus A330-200F can carry:
5800 x 30 = 174000 units.
According to official sources and as reported in the press, the first wave of
vaccine will be 8 million units, it means:
8000000 / 174000 = 46 flights.
And finally, it remains to multiply the cost of the flight from the country from
where we will carry the vaccine by the number of flights to Ukraine, thereby we
find out how much it will cost Ukraine to bring the first batch (8 million doses out
of 40, where 40 is the approximate population of Ukraine):
TOTAL COST = 31003$ × 46 = 1 426 138$.
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3.4 Conclusions of Design part
The Ministry of Health has already calculated that for the vaccination of all
priority groups, Ukraine will need 16 million doses of the vaccine - or 32 million
in the case of a double vaccination. And if Ukraine receives eight million doses -
half  of  this  number - within the framework of  the COVAX initiative,  then the
country will have to buy the other half at the full price.
According to him, both legally and financially, Ukraine is ready to purchase a
future vaccine produced by any company - provided that the safety of the drug is
proven,  it  will  pass  all  stages  of  testing  with  international  confirmation  of  its
effectiveness and will be officially registered on the international market.
In this part,  by means of calculations, the cost of one flight to deliver the
vaccine to Ukraine was calculated. The total cost of the flight is 31003$.
Further, it was calculated how many packages will fit on one aircraft, thus it
is possible to calculate the number of necessary flights for delivery. According to
official sources and as reported in the press, the first wave of vaccine will be 8
million units, it means 46 flights.
And finally, it remains to multiply the cost of the flight from the country from
where we will carry the vaccine by the number of flights to Ukraine, thereby we
find out how much it will cost Ukraine to bring the first batch: 1 426 138$.
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Infectious  substances  in  Category  A  will  not  be  accepted  for  shipment
through postal services. Infectious substances in Category B may be shipped by
registered  air  mail,  and the  Universal  Postal Union recommends  the  following
procedure.
The basic triple packaging system is used with the same requirements as for
other  means of  transport. The address  label  shall  display  the  word “Lettre”  or
“Letter”  and  the  green  Customs  Declaration   WHO/CDS/CSR/LYO/2005.22
Guidance on regulations for the transport of infectious substances. Label for Postal
Mail  is  required  for  international  mailing.  “DIAGNOSTIC  SPECIMENS”,
“CLINICAL SPECIMENS” or “BIOLOGICAL SUBSTANCE, CATEGORY B”
shall be identified with the white diamond label with black letters “UN 3373”.
Local/international restrictions may be in force. Prior contact should therefore
be  made  with  thenational  public  operator  to  ascertain  whether  the  packaged
material will be accepted by the postal service in question.
Statistical  data  collected  by  a  group  of  central  laboratories  showed  the
efficacy of packaging compliant with P650 and P620 in assuring that infectious
substances  are  transported  without  leakage  and  loss  of materials.  For  the  4.92
million  primary  containers  shipped  in  2003  to  any  of  the  worldwide  regional
offices  of  these  central  laboratories,  just  106  breakages,  0.002%  of  the  total
number, were recorded. Moreover, the leakages that did occur were all contained
by  the  absorbent  material,  and  no  damage  to secondary  containers  or  outer
packagings was reported.
CEPI classifies development stages for vaccines as "exploratory" (planning
and designing a candidate, having no evaluation in vivo), "preclinical" (in vivo
evaluation with preparation for manufacturing a compound to test in humans), or
initiation  of  Phase  I  safety  studies  in  healthy  people. Some 321  total  vaccine
candidates are in development as either confirmed projects in clinical trials or in
early-stage "exploratory" or "preclinical" development, as of September.
Definition of vaccine safety, efficacy, and clinical endpoints in a Phase III
trial  may  vary  between  the  trials  of  different  companies,  such  as  defining the
128
degree  of  side  effects,  infection  or  amount  of  transmission,  and  whether  the
vaccine prevents moderate or severe COVID-19 infection.
During analitycal part was selected Wizz Air airline cause during analysis
was shown, very stable in the air carrier market. I also have a good fleet of the
latest aircraft, including for the transport of dangerous goods such as medicines.
He also has a colossal  and successful  experience in the transportation of  ADR
cargo. Everything is performed to the highest IATA standards.
And it is a stable airline that, during the COVID-19 pandemic, managed to
maintain its leadership position in the air carrier market. And also without reducing
the working staff, which numbers thousands of people.
It  was  found  that  among  the  most  important  factors  for  special  cargo
companies  are:  cost  minimization,  maximizing  supply  efficiency,  complexity
management,  maximizing  supply  flexibility  and  minimizing  risks.  Emphasis  is
placed on the nonlinearity of the links between these factors and the solution of the
multicriteria problem by the participants of the logistics supply chain, which, in
particular, makes it difficult to develop the relevant developments.
Ukraine is ready to purchase a future vaccine produced by any company -
provided that the safety of the drug is proven, it will pass all stages of testing with
international confirmation of its effectiveness and will be officially registered on
the international market.
One flight to deliver the vaccine to Ukraine was calculated. The total cost of
the flight is 31003$.
Further, it was calculated how many packages will fit on one aircraft, thus it
is possible to calculate the number of necessary flights for delivery. According to
official sources and as reported in the press, the first wave of vaccine will be 8
million units, it means 46 flights.
And finally, it remains to multiply the cost of the flight from the country from
where we will carry the vaccine by the number of flights to Ukraine, thereby we
find out how much it will cost Ukraine to bring the first batch: 1 426 138$.
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